Photo of Bexis

Not too long ago we wrote about McKenzie v. Progressive Treatment Solutions, LLC, 2026 WL 636741 (N.D. Ill. March 6, 2026).  One of the things about McKenzie that caught our eye was the statement that, under Illinois law, “misrepresentations or mistakes of law cannot form the basis of a claim for fraud.”  Id. at *6 (quoting McIntosh v. Walgreens Boots Alliance, Inc., 135 N.E.3d 73, 84 (Ill. 2019)).  As our prior post explained, the non-fraudulent legal statement at issue in McKenzie was a purported misrepresentation of “the product’s regulatory classification.  That alleged conduct is not an actionable representation of fact.”

We see those kinds of claims fairly frequently in prescription medical product liability litigation – allegations about some FDA requirement or another that was supposedly misstated or misapplied either by a regulated manufacturer or someone else in the chain of distribution (allegedly calling a §510(k) device ”approved” rather than ”cleared” comes to mind).  So, the Illinois law proposition that allegations of legal mistakes are insufficient to support a fraud – or consumer fraud – claim seems important.  But it was not something we had encountered before in the context of what we discuss on the Blog.

So we thought we’d take a look.  Also, the firm’s AI folks had just told us that one of our newly available products could generate 50-state surveys.  We’ve never used AI for that kind of thing (or much of anything at all – Bexis is not much of a fan).  So we also thought that we’d use that AI feature for a first cut of the survey, and see how good it is at finding the answer to a legal question on a state-by-state basis.

The good thing about AI is that it didn’t take much time – under 10 minutes – to generate what it called a survey.  See the end of this post for the rest.

One thing we quickly learned is that the First and Second Restatements of Torts §525 include legal misrepresentations as actionable fraud (“One who fraudulently makes a misrepresentation of fact, opinion, intention or law. . . .  ”).  AI completely missed restatements as a source of law, although occasionally cited to cases that cited them.  But once again it is questionable whether this ALI (“Always Liability Increases”) restatement actually restates the law.  The proposition that a legal misrepresentation cannot be the basis of a fraud claim has ancient roots.

A representation of what the law will or will not permit to be done is one on which the party to whom it is made has no right to rely; and if he does so it is his folly, and he cannot ask the law to relieve him from the consequences.

Upton v. Tribilcock, 91 U.S. 45, 50 (1875).  Likewise, the Restatements notwithstanding, rejection of legal misrepresentations as fraud still looks like the majority rule.  E.g., United States ex rel. Schutte v. SuperValu Inc., 598 U.S. 739, 756 (2023) (“many courts appear to have stated − as a general rule − that misrepresentations of law are not actionable at common law”) (applying similar principles to the False Claims Act) (citation omitted).

Also, this survey is somewhat different from those we usually research on the Blog.  Most of our surveys are for issues directly involving prescription medical product liability litigation.  This one isn’t (another reason we tried AI).  Nearly all of the cases for the proposition that legal statements cannot constitute fraud are not drug/device cases.  So here, we’re not trying to be comprehensive.  We’re simply looking for a firm indication whether each jurisdiction follows this general rule.

One last caveat:  There are a couple of well-recognized exceptions to legal misstatements not being fraud:  (1) fiduciary relationship cases, particularly those involving lawyers accused of misleading their clients about legal issues; and (2) “superior knowledge” by the party accused of misrepresentation.  Manufacturers and sellers of prescription medical products are not fiduciaries, although doctors might be.  “Superior knowledge” can be mushier.

So here we go.

Alabama

Alabama follows the same rule as Illinois.  “[T]he alleged misrepresentation in this case was a misstatement of law, which is not actionable.”  Johnson v. Sorenson, 914 So.2d 830, 839 (Ala. 2005).  Here is a recent example:

Alabama courts have repeatedly held that misrepresentation or concealment as to a matter of law cannot constitute remedial fraud, because everyone is presumed to know the law, and therefore cannot in legal contemplation be deceived by erroneous statements of law.  Such representations are ordinarily regarded as mere expressions of opinion on which the hearer has no right to rely.  The Alabama Supreme Court recently reiterated that the law is presumed to be known by all.

Gill v. GMAC Insurance Co., 2009 WL 103189, at *3 (M.D. Ala. Jan. 14, 2009) (citations omitted).

Alaska

As usual, not much in Alaska.  A really old – pre-statehood – case held, back in 1946, that “in the absence of actual fraud, those misled may not complain.  They are presumed to know the law equally with those who misstate it.”  In Re Town of Sitka, Alaska, 11 Alaska 201, 208 (D. Alaska 1946).  A much more recent case, Lightle v. State, Real Estate Commission, 146 P.3d 980, 984 (Alaska 2006), quotes Restatement §525’s language including “law,” but that decision did not address this issue.  See Bubbel v. Wien Air Alaska, Inc., 682 P.2d 374, 382-83 (Alaska 1984) (discussing “the question of whether a claim for relief may arise from a misrepresentation of law,” but reaching a decision on a different issue while “declin[ing] to adopt a flat rule that misrepresentations of law are not actionable in this state”).

Arizona

In Arizona “a misrepresentation of law or of the legal effect of a contract does not constitute actionable fraud.”  Barnes v. Lopez, 544 P.2d 694, 697 (Ariz. App. 1976).  Accord Pleasants v. Home Federal Savings & Loan Ass’n, 569 P.2d 261, 264 (Ariz. App. 1977) (following Barnes).  However, the Arizona Supreme Court has been rather lax in applying that rule, at least in the settlement context.  See Love v. Home Transportation Co., 641 P.2d 854, 856 (Ariz. 1982) (to “[a] person . . . untutored in the law” a statement about “illegality” could be an “opinion”).  Also, the “broader” scope of the Arizona consumer fraud statute does not include such a limitation.  Cearley v. Wieser, 727 P.2d 346, 348 (Ariz. App. 1986).

Arkansas

Arkansas also prohibits fraud claims based on alleged legal misrepresentations.

As a general rule, fraud cannot be predicated upon misrepresentations as to matters of law, nor upon opinions on questions of law based on facts known to both parties alike, nor upon representations as to what the law will not permit to be done. . . .  Reasons given for this rule are that every one is presumed to know the law, both civil and criminal, and is bound to take notice of it, and hence has no right to rely on such representations or opinions, and will not be permitted to say that he was misled by them.

Pambianchi v. Howell, 265 S.W.3d 788, 792 (Ark. App. 2007) (quoting Adkins v. Hoskins, 3 S.W.2d 322, 326 (Ark. 1928) (citation omitted).  Accord Rice v. Ragsdale, 292 S.W.3d 856, 864 (Ark. App. 2009) (“[a]s a general rule, fraud cannot be predicated upon misrepresentations as to matters of law”).

California

That misstatement of law cannot be fraud in California has been the law for quite some time:

[T]hese representations . . . did not constitute fraud in the legal sense.  They were not statements of fact but at most misrepresentations of law.  It is well settled that such misrepresentations, at least where there is no relation of trust or confidence between the parties, do not amount to fraud. . . .  Whether the true ground for the rule be that everyone is presumed (or rather, bound) to know the law, or that a representation regarding the law constitutes an expression of opinion upon which the party to whom it is addressed has no right to rely, the rule itself is thoroughly well settled.

Haviland v. Southern Cal. Edison Co., 158 P. 328, 331 (Cal. 1916) (citations and quotation marks omitted).  “[A]bsent special circumstances, misrepresentations of law do not amount to actionable fraud.”  Bledsoe v. Watson, 106 Cal. Rptr. 197, 200 (Cal. App. 1973) (citation omitted).  Thus, “[i]t is well settled . . . that misrepresentations of the law are not actionable as fraud, including under the mail and wire fraud statutes, because statements of the law are considered merely opinions and may not be relied upon absent special circumstances.”  Sosa v. DIRECTV, Inc., 437 F.3d 923, 940 (9th Cir. 2006).  See Miller v. Yokohama Tire Corp., 358 F.3d 616, 621 (9th Cir. 2004) (“fraud cannot be predicated upon misrepresentations of law or misrepresentations as to matters of law” because “[s]tatements of domestic law are normally regarded as expressions of opinion which are generally not actionable in fraud even if they are false”) (RICO case following California law as to the “established common law” of fraud).  See also Cal. Civ. Code §1710 (“deceit” involves false assertions of “fact”).

Colorado

In Brodeur v. American Home Assurance Co., 169 P.3d 139 (Colo. 2007), an alleged misrepresentation of authorization for use of a prescription drug could not be the basis of a fraud claim:

[T]he misrepresentation arose from the implication that the [drug] treatment had not already been authorized − an incorrect representation of a matter of law.  The misrepresentation that the treatment had not been authorized is an incorrect opinion of the legal meaning and effect of the regulations. Thus, [it] was a misrepresentation of law, not a misrepresentation of fact. . . .  As a statement of [defendant’s] opinion on a matter of law, [it] is not actionable under the general rule that requires a misrepresentation of fact.

Id. at 153-54.  “[A] representation of law is a statement of opinion as to what the law permits or prohibits, and cannot support an action for fraud.”  Id. at  153 (citation omitted).

Connecticut

We’re not at all sure that Connecticut follows the fact/law distinction.  Crowther v. Guidone, 441 A.2d 11 (Conn. 1981), held:

To require the representation to be made as a statement of fact, however, is quite different than to require that the statement be factual as opposed to legal. . . .  The latter inquiry in which the defendants would have us engage seeks to erect a barrier to shield from liability those defendants whose misrepresentation happens to concern the law.  We decline to license such deceit.

Id. at 13.

Delaware

Delaware probably follows the rule that legal statements cannot support fraud claims.  “All persons are presumed to know the law, including laypersons,” therefore “courts have declined to recognize a misrepresentation as to a matter of law as a basis for a charge of fraud or deceit in making a contract.”  Thomas v. Nationstar Mortgage, LLC, 2015 WL 5766775, at *2 n.20 (Del. Ch. Sept. 18, 2015).  Thomas cited Wal-Mart Stores, Inc. v. AIG Life Insurance Co., 872 A.2d 611, 629 (Del. Ch. 2005), wherein the chancery court held:

[Plaintiff’s] allegation that the [defendants] assured it [about] complian[ce] with the Internal Revenue Code does not state a claim upon which relief can be granted.  It is an opinion as to a matter of law.  A misrepresentation as to a matter of law is a statement of opinion only and cannot afford a basis for a charge of fraud or deceit in the making of the contract.  This is because all persons are presumed to know the law and therefore cannot be deceived by erroneous statements of law.

Id. at 629 (footnotes omitted).  The Delaware Supreme Court did not reject this rule, but reversed the result, holding that the relevant statements “implied facts” that were “known to the maker,” and thus involved more than legal opinions.  Wal-Mart Stores, Inc. v. AIG Life Insurance Co., 901 A.2d 106, 115-16 (Del. 2006).

District of Columbia

The District has “recognize[d] . . . the general rule that misrepresentations as to matters of law do not ordinarily support an action for damages.”  Hembry v. Parreco, 81 A.2d 77, 79 (D.C. Mun. 1951) (citation omitted).  Thus,

[B]ecause the relevant misrepresentation in the instant case was not a misrepresentation of fact upon which [defendant] could base his belief in the legality of his acts; rather, the relevant assurance was a misrepresentation of law.  As cases in this jurisdiction have held, “it is the general rule that misrepresentations as to matters of law do not ordinarily support an action for damages.”

Democratic National Committee v. McCord, 416 F. Supp. 505, 507 (D.D.C. 1976) (quoting Hembry).

Florida

Florida follows “the principle that fraud cannot be predicated upon misrepresentations of law or misrepresentations as to matters of law.”  Marks v. Fields, 36 So.2d 612, 614 (Fla. 1948) (citation and quotation marks omitted).  “It is, of course, well settled in Florida that in order to be actionable a fraudulent misrepresentation must be of a material fact, rather than a mere opinion or a misrepresentation of law.”  Chino Electric, Inc. v. U.S. Fidelity & Guarantee Co., 578 So.2d 320, 323 (Fla. App. 1991) (footnote omitted).  However, “the modern trend of cases is to find statements of fact implied in otherwise material misrepresentations which have some legal character.”  Id.

Georgia

In Georgia, “[t]he law is well settled that fraud cannot be predicated upon misrepresentations of law or misrepresentations as to matters of law.”  Parrish v. St. Joseph’s/Candler Health System, Inc., 874 S.E.2d 413, 419 (Ga. App. 2022).

[A] misrepresentation as to a matter of law is a statement of opinion only and can not afford a basis for a charge of fraud or deceit in the making of the contract.  This is because all persons are presumed to know the law and therefore cannot be deceived by erroneous statements of law.

BPP069, LLC v. Lindfield Holdings, LLC, 816 S.E.2d 755 (Ga. App. 2018) (quoting and following Lakeside Investments Group v. Allen, 559 S.E.2d 491, 493 (Ga. App. 2002)).

Hawai’i

As with Alaska, the strongest statement in Hawai’i is old enough to predate statehood.  See Kyles v. Lantis, 39 Haw. 440, 444 (Haw. 1952) (applying “the well-settled general rule that fraud cannot be predicated upon misrepresentations of law or misrepresentation as to matters of law”).  In a RICO case, a Hawai’i court recently followed the “routine” rule that “a legal representation . . . is not an actionable theory of fraud.”  Bolos v. Waldorf-Astoria Management LLC, 762 F. Supp.3d 975, 1013 (D. Haw. 2025) (citation omitted).  A contrary view was expressed in Elliot Megdal & Associates v. Hawaii Planing Mill, Ltd., 814 F. Supp. 898 (D. Haw. 1993), which refused to follow Kyles and would “abandon the distinction between statements of fact and law.”  Id. at 904.

Idaho

An Idaho appellate court has held that reliance on a statement of law sufficient to support a claim of fraud does not exist:

Even if we assume, though, that [defendant] made this false statement to [plaintiff], we hold that [plaintiff] could not justifiably rely on it.  Such a statement by [defendant] would have been [plaintiff’s] legal opinion as to [plaintiff’s] rights and status. . . .  Such a statement of law is a mere assertion of opinion, upon which [plaintiff] had no right to rely.

Mitchell v. Barendregt, 820 P.2d 707, 714 (Idaho App. 1991).

Illinois

The Illinois Supreme Court case that McKenzie followed stated, with citations for every proposition:

It is understood that misrepresentations or mistakes of law cannot form the basis of a claim for fraud.  An erroneous conclusion of the legal effect of known facts constitutes a mistake of law and not of fact.  Because all persons are presumed to know the law, a mistake or misrepresentation of law . . . is discoverable by the plaintiff in the exercise of ordinary prudence, [and] cannot form the basis of an action for fraud.

McIntosh v. Walgreens Boots Alliance, Inc., 135 N.E.3d 73, 84 (Ill. 2019) (citations omitted).

Indiana

The status of the law/fact distinction for purposes of fraud in Indiana is rather unclear.  More than a century ago the Indiana Supreme Court held, “[o]n the question of fraudulent representations, it may be conceded that there is no fraud in a representation as to the law of the state of the domicile of the party to whom the representation is made.”  Travelers’ Protective Ass’n v. Smith, 107 N.E. 283, 287 (Ind. 1914).  In Lawyers Title Insurance Corp. v. Pokraka, 595 N.E.2d 244 (Ind. 1992), the court questioned the distinction but declined to overrule prior precedent:

The appellate court, citing Travelers’ Protective Ass’n, determined that this was not actionable fraud, in part because it was a misrepresentation of law and not a misrepresentation of fact.  Although this precept has never been explicitly repudiated by this Court, . . . we note that the present tendency is strongly in favor of eliminating the distinction between misrepresentations of law and facts . . . .  We need not decide whether Travelers continues to be an accurate statement of the law on this issue.

Id. at 249 (citations and quotation marks omitted).

However, no subsequent Indiana decision has followed up on this issue, and lower Indiana courts have continued to apply the distinction.  See American United Life Insurance Co. v. Douglas, 808 N.E.2d 690, 703 (Ind. App. 2004) (“in general, a misstatement of law cannot form the basis of fraud because everyone is presumed to know the law and therefore, the allegedly defrauded party cannot justifiably have relied on the misstatements”); Bowman v. City of Indianapolis, 133 F.3d 513, 518 (7th Cir. 1998) (“because the Pokraka court expressly declined to eliminate the distinction, we think it appropriate to apply the law as it currently stands and to leave any major change in doctrine to the Indiana judiciary”).

Iowa

Iowa follows general rule that “[r]epresentations or statements concerning domestic law normally are not regarded as representations of fact and therefore no action for fraud arises even when they are false.”  State v. Tyler, 512 N.W.2d 552, 555 (Iowa 1994) (citations omitted).

[T]here is a distinction between a misunderstanding as to the law and false assertions of fact. . . .  That a misrepresentation or misunderstanding of the law will not vitiate a contract, where there is no misunderstanding of the facts is well settled. . . .  [A]n expression of opinion which is a matter of law cannot constitute false representations or deceit.

International Milling Co. v. Gisch, 137 N.W.2d 625, 631 (Iowa 1965).

Kansas

It’s hard to say what the current law in Kansas is.  Back in 1931 the Kansas Supreme Court applied the “rule” that “a misrepresentation on the question of law would not justify the setting aside of the release.”  Ertman v. Clemens Coal Co., 297 P. 431, 432 (Kans. 1931).  A few years earlier, that court likewise recognized “the well-established proposition . . . that a settlement will not be set aside because one of the parties did not understand its legal effect” because “persons of sound and mature mind are presumed to know the law,” Cramer v. Kansas City Railways Co., 211 P. 118, 119 (Kans. 1922), but with an exception that mistakes of law can be actionable “where the opposite party was in some way instrumental in producing the result.”  Id.  Similar is Epp v. Hinton, 138 P. 576, 577 (Kan. 1914), where the general rule that “a false representation as to a matter of law will not support an action for deceit, because it is essentially an expression of opinion” was modified with an exception for the “law of another state.”  Id. at 577.

All of this law is old, and we haven’t seen anything in a Kansas decision, state or federal court, more recent that is definitive on this point.

Kentucky

The rule in Kentucky was stated by its high court in McDonald v. Goodman, 239 S.W.2d 97, 99 (Ky. 1951).

[M]isrepresentation or concealment as to a matter of law can not constitute actionable fraud because every one is presumed to know the law and therefore can not, in legal contemplation, be deceived by erroneous statements of the law, and such representations are ordinarily regarded as mere expressions of opinion, on which the hearer has no right to rely.

Id. at 99 (quoting Tewmey v. Tewmey’s Assignee, 65 S.W.2d 479, 481 (Ky. 1933)); Moseley v. Owensboro Municipal Housing Commission, 252 S.W.2d 880, 881 (Ky.1952) (“A false representation as to law does not amount to fraud, in the absence of a trust or confidential relation between the parties.”).  This rule has been followed by comparatively recent Kentucky appellate precedent.

[A]ppellants assert their fraudulent misrepresentation claims were based upon a legal misrepresentation, rather than a factual misrepresentation . . . .  Taken at face value, there are a multitude of problems with this argument.  One is that in the absence of a trust or confidential relation between the parties − a relation the appellants have never alleged to have existed herein − a false representation as to the law, and by extension the legal effect of a written instrument, does not amount to fraud.

Reesor v. City of Audubon Park, 2017 WL 2609243, at *5-6 (Ky. App. June 16, 2017) (unpublished) (citations, including to McDonald, and footnote omitted) (emphasis original); In re Backer, 51 F. Appx. 522, 531 (6th Cir. 2002) (“Generally, Kentucky law does not recognize misrepresentations of law, only misrepresentations of fact, unless a confidential or trust relationship exists between the parties.”) (citations omitted); Compressed Gas Corp., Inc. v. U.S. Steel Corp., 857 F.2d 346, 351 (6th Cir. 1988) (a “representation, to the extent that it is a misrepresentation of law, is not actionable in Kentucky”). 

Louisiana

Louisiana may not follow the prohibition of fraud claims based on allegations of legal misrepresentations.  In Petrohawk Properties, L.P. v. Chesapeake Louisiana, L.P., 689 F.3d 380 (5th Cir. 2012), the court – generalizing from a Louisiana case involving allegations of lawyer misconduct – held:

[W]e reject [appellant’s] argument that a misrepresentation of law cannot give rise to a fraud claim.  Under Louisiana law, the relevant inquiry is whether there was a misrepresentation, suppression, or omission of true information.  Indeed, Louisiana courts have found fraud where the underlying false statement was a misrepresentation of law.

Id. at 389 (citing Lupo v. Lupo, 475 So.2d 402 (La. App. 1985) (involving a lawyer deceiving his client)).

But that’s all we’ve been able to find in Louisiana.  We also note that Louisiana, uniquely, is a code, rather than common-law, state – and the Louisiana Code provisions concerning fraud, La. Civ. C. §§1953-57, do not distinguish between misrepresentations of fact and of law.

Maine

There is not much recent law in Maine.  Dictum in State v. Deschambault, 191 A.2d 114 (Me. 1963), referencing a case from 1883, stated that “a statement of law . . . was not a fact on which to ground deceit.”  Id. at 117.  But Deschambault was a criminal case.  In Weaver v. New England Mutual Life Insurance Co., 52 F.Supp.2d 127 (D. Me. 1999), the court rejected the plaintiff’s reliance on Restatement §525, “or the purpose of expanding the scope of actionable fraud claims.”  Id. at 133.  “Defendants are correct in its assertion that under Maine law a claim for fraud must be based on a misrepresentation of fact.”  Id.  But Weaver “did not confine its analysis” to the “conclusions about . . . legal effect” that the defendant argued were the sole bases of the plaintiff’s fraud claim.  Id. at 132.

Maryland

In Maryland a defendant that “has acted on the opinion of his attorneys in making a statement,” cannot be liable for fraud “if he did so honestly.”  Brashears v. Collison, 115 A.2d 289, 294 (Md. 1955).  Citing Brashears, a more recent decision held:

Whether a contract requires the disclosure of a particular matter is a question of contract interpretation and is properly regarded as a legal matter. . . .  Seeking and relying upon the advice of an attorney not only constitutes no evidence of fraud, but it is evidence of the contrary.

VF Corp. v. Wrexham Aviation Corp., 715 A.2d 188, 198 (Md. 1998).  See Blonder v. Buckhantz, 2006 WL 8456524, at *6 (n.8 D. Md. Feb. 16, 2006) (“legal opinions . . . cannot be as a matter of law, fraudulent statements”; a statement that “is clearly a matter of law which is not fraudulent”).

This precedent suggests that Maryland law does not predicate fraud on alleged legal misstatements, but we cannot state that the rule is firmly established.

Massachusetts

Massachusetts probably allows fraud claims based on allegations of misstatements of law – at least in “business transactions” −  as its high court adopted the standard set in Restatement §525:

The elements necessary to maintain an action in deceit are summarized in Restatement: Torts, §525: “One who fraudulently makes a misrepresentation of fact, opinion, intention or law for the purpose of inducing another to act or refrain from action in reliance thereon in a business transaction is liable to the other for the harm caused to him by his justifiable reliance upon the misrepresentation.”

Graphic Arts Finishers, Inc. v. Boston Redevelopment Authority, 255 N.E.2d 793, 796 (Mass. 1970).

Some uncertainty arises because misstatements of law were not at issue in Graphic Arts, and earlier Massachusetts Supreme Judicial Court precedent had specifically barred fraud/deceit claims based on legal misrepresentations.  See Galassi Mosaic & Tile Co. v. City of Boston, 4 N.E.2d 291, 294 (Mass. 1936) (“It if be assumed that the quoted representation was a misrepresentation as to the effect of the statutory provision . . . and therefore false, the defendant cannot be liable for a false representation of law.”); cf. Cellucci v. Sun Oil Co., 320 N.E.2d 919, 925 (Mass. App. 1974) (applying “superior knowledge” exception to allow a fraud claim based on a “misrepresentation of law” suggesting the general rule still existed), aff’d on other grounds, 331 N.E.2d 813 (Mass. 1975).

Michigan

The Michigan Supreme Court acknowledged that “[i]t is the general rule that fraud cannot be predicated upon misrepresentations as to matters of law” in Rosenberg v. Cyrowski, 198 N.W. 905, 906 (Mich. 1924) (citation and quotation marks omitted).  But Rosenberg involved attorney statements, so an exception applied.  Id. at 906-07.  The general rule still seems to hold in Michigan.  Cummins v. Robinson Township, 770 N.W.2d 421, 435 (Mich. App. 2009) (“alleg[ations] that defendants made intentional, inaccurate statements regarding the law” cannot support “a viable fraud claim”); Dugan v. Vlcko, 2018 WL 5995482, at *5 (E.D. Mich. Nov. 15, 2018) (“it is correct that Michigan courts have found that, in most circumstances, misrepresentation of the law is not grounds for fraud claims”) (citations omitted); DIRECTV, Inc. v. Rayborn, 2003 WL 23200248, at *5 (W.D. Mich. Oct. 20, 2003) (plaintiff “cannot maintain a claim for fraud based upon [defendant’s] interpretation of federal law. . . .  The general rule is that fraud cannot be based upon a misrepresentation of law.”) (citation omitted) (one of several identical decisions).

Minnesota

The Supreme Court of Minnesota followed the rule legal fraud is not actionable, with the usual exceptions, in State v. Edwards, 227 N.W. 495 (Minn. 1929):

[I]gnorance of the law is no excuse.  Indeed it is a necessary principle or rule lying at the foundation of government.  This rule sounds in policy. . . .  It is best to adopt the theory that the rights and responsibility of every one shall be the same as if he, in fact, knew the law.  Ordinary vigilance will disclose the truth or falsehood of representations as to matters of law. . . .  It does not apply when the relation of trust and confidence is involved.  It is sufficient for present purposes to state that the general rule, which controls in this case, may be rendered inapplicable by peculiar facts and circumstances.

Id. at 495-96 (citations omitted).  That’s still essentially Minnesota law.

[A]bstract statements of law or pure legal opinions are not actionable; however, a mixed statement of law and fact may be actionable if it amounts to an implied assertion that facts exist that justify the conclusion. . . .  A representation of law that is clearly a statement of opinion does not carry an implication of fact and is not actionable.

Hoyt Properties, Inc. v. Production Resource Group., L.L.C., 736 N.W.2d 313, 318 (Minn. 2007) (citations and quotation marks omitted).  Accord Northernaire Productions, Inc. v. County of Crow Wing, 244 N.W.2d 279, 281 (Minn. 1976) (“[g]enerally, misrepresentation of law is not actionable”) (citation omitted); Lonergan v. Ellison, 2021 WL 5289553, at *3 (Minn. App. Nov. 15, 2021) (“misrepresentations of law are generally not actionable for fraud”) (citation omitted); Gatz v. Frank M. Langenfeld & Sons Construction, Inc., 356 N.W.2d 716, 718 (Minn. App. 1984) (“Misrepresentations of law are not actionable.”) (citation omitted).

Mississippi

In Mississippi, “[t]raditionally, a misrepresentation upon which an action for fraud is predicated must be a representation of fact and not a representation of the law.”  Johnson v. Brewer, 427 So.2d 118, 121 (Miss. 1983) (citations omitted) (citing Harrison v. Vermillion, 56 So. 2d 811, 814 (Miss. 1952) (“Fraud could not be predicated upon” “the expression of a legal opinion”)).

Missouri

Missouri follows “the rule that one is not permitted to say that he has been misled as to a matter of law,” recognizing common exceptions for “confidential relationship” and “superior knowledge.”  White v. Mulvania, 575 S.W.2d 184, 192 (Mo. 1978).  Thus, “[t]he general rule is that expressions of opinion, such as to a future event or for matters of law, are not sufficient for a fraud action.”  Reis v. Peabody Coal Co., 997 S.W.2d 49, 65 (Mo. App. 1999).  “[I]t has been consistently held that an action for fraud cannot be based upon a misrepresentation of law.”  Uhle v. Sachs Electric, 831 S.W.2d 774, 778 (Mo. App. 1992) (citation omitted).

The defendants concede the existence of the general rule that an action for fraud (and also an affirmative defense of fraudulent misrepresentation) cannot be based on misrepresentations of law.  That rule is based on the principle that everyone is presumed to know the law and is bound to take notice of the law and, therefore, in legal contemplation, cannot be deceived by representations concerning the law or permitted to say he has been misled.

*          *          *          *

[W]e find no error in the trial court’s conclusions that the misrepresentations were not actionable because they were misrepresentations of law.

Lucas v. Enkvetchakul, 812 S.W.2d 256, 260 (Mo. App. 1991) (citation omitted).  Accord Bowles v. All Counties Investment Corp., 46 S.W.3d 636, 639 (Mo. App. 2001) (quoting and following Lucas).

Montana

In Montana, “[g]enerally, fraud must be premised upon a misrepresentation of material fact, rather than law.”  Ryckman v. Wildwood, Inc., 641 P.2d 467, 471 (Mont. 1982).  “[O]ne cannot perpetrate fraud upon another by making any statement or representation as to the scope, operation, or effect of an existing law.”  Russell v. Sunburst Refining Co., 272 P. 998, 1005 (Mont. 1928).  See Emerson-Brantingham Implement Co. v. Anderson, 194 P. 160, 164 (Mont. 1920) (“misrepresentation or opinion expressed . . . as to what the law is relative to their respective rights in the matter, . . . is not a fraudulent misrepresentation”); H&R Block Tax Servs. LLC v. Kutzman, 2010 WL 11531369, at *4 (D. Mont. April 21, 2010) (“Because the Counterclaim only alleges a misrepresentation of an opinion on the law, . . . [it] is dismissed.”).

The usual exceptions apply.

Nebraska

With the usual exceptions, “[i]t is a general rule that misrepresentations as to law will not give rise to an action for fraud and deceit.”  Loringer v. Kaplan, 137 N.W.2d 716, 718 (Neb. 1965).  “It has frequently been held that a misrepresentation as to the law will not give rise to an action for fraud and deceit and, therefore, cannot be said to constitute conduct which amounts to a false representation or concealment of material facts.”  Kohlbeck v. City of Omaha, 318 N.W.2d 742, 745 (Neb. 1982).  “Generally a mistake of law is one upon which a party cannot rely, as all parties are bound to know the law.”  Abbott v. Abbott, 195 N.W.2d 204, 208 (Neb. 1972) (citation omitted).  See Agrex, Inc. v. City of Superior, 581 N.W.2d 428, 436 (Neb. App. 1998) (quoting and following Kohlbeck).

Nevada

There’s not much in Nevada.  Hernandez v. Creative Concepts, Inc., 862 F. Supp.2d 1073 (D. Nev. 2012), recognized, following cases applying California law, that “[a]s a general rule, fraud cannot be predicated upon misrepresentations of law or misrepresentations as to matters of law.”  Id. at 1094.  That decision listed :four exceptions”:  special knowledge, fiduciary relationship, affirmatively obtaining the plaintiff’s confidence, and “some other special reason to expect” reliance.  Id.

New Hampshire

The New Hampshire Supreme Court held, in DePalantino v. DePalantino, 658 A.2d 1207, 1209 (N.H. 1995):

Assuming that the plaintiff made these statements, as a matter of law they are insufficient. . . .  The statements constitute no more than the plaintiff’s opinion regarding the status of the law. . . .  Opinions regarding the status or interpretation of the law, however, generally will not provide the basis for an action for fraud or misrepresentation.

Id. at 1209 (citation omitted).

New Jersey

A century ago, one of the predecessors of the New Jersey Supreme Court held that, “[i]f the only misrepresentation was . . . as to the legal effect of the writing which defendant signed, that was not a fraudulent representation.”  Wiebke v. De Wyngaert, 101 A. 410, 410-11 (N.J. Ch. 1917).  Citing Wiebke, a less ancient decision held:

[S]tatements of law do not generally constitute fraud. . . .  A representation of what the law will or will not permit to be done is one on which the party to whom it is made has no right to rely.  It is an opinion. . . .  An exception to this rule exists where an expert possessed of superior knowledge.

PH Chaleyer, Inc v. Simon, 91 F. Supp. 5, 7 (D.N.J. 1950) (citations and quotation marks omitted).  Chaleyer, in turn, was cited as stating the law of New Jersey in a much more recent decision, that the defendant’s “representations . . . are interpretations of the loan agreement and therefore are statements of law, which cannot constitute fraud.”  Wu v. Capital One, N.A., 2014 WL 3673041, at *7 (D.N.J. July 22, 2014), aff’d on other grounds, 617 F. Appx. 214 (3d Cir. 2015).

On the other hand, a New Jersey trial court did cite the Restatement §525’s “or law” language in National Premium Budget Plan Corp. v. National Fire Insurance Co., 234 A.2d 683, 704 (N.J. Super. Law. Div. 1967), aff’d, 254 A.2d 819 (N.J. Super. App. Div. 1969), a case having nothing to do with allegations of legally related fraud.

We thought there would be more precedent in New Jersey, but we (and the AI program) didn’t find it.

New Mexico

A pair of New Mexico Supreme Court decisions from the 1950s acknowledge the general rule.  Agnew v. Landers, 278 P.2d 970 (N.M. 1954), held:

[T]he authorities seem reasonably uniform to the effect that a misrepresentation of the law cannot constitute actionable fraud.  This conclusion is sometimes based upon the theory that fraud cannot be predicated upon the expression of an opinion.  We feel that this representation in the instant case is not actionable.

Id. at 977 (citation omitted).  Rogers v. Stacy, 318 P.2d 1116, 1118 (N.M. 1957), recognized the general rule that misrepresentations of law are not actionable,” but applied the fiduciary relationship exception.  We didn’t find anything more recent that would call those decisions into question.

New York

New York law holds that “a pure opinion of law . . . may not, except in unusual circumstances, base an action in tort,” and “a mixed statement of fact as to what the law is or whether it is applicable,” which can be actionable.  National Conversion Corp. v. Cedar Building Corp., 246 N.E.2d 351, 355 (N.Y. 1969).  “Hence, in the proper circumstances there may indeed be reliance on a fraudulently expressed statement of the law.”  Id. at 356.  “[A]ll persons are treated as if they knew the law in passing on the character of their acts” so that “a representation of law which is to be taken as the expression of an opinion only.”  Municipal Metallic Bed Manufacturing Corp. v. Dobbs, 171 N.E. 75, 76 (N.Y. 1930).  But this rule only applies “[w]hen one knows the facts.”  Id.

Thus, under New York law, “a representation based on a good faith misinterpretation of the legal effect of an agreement does not provide a basis for a fraud claim,” but “[e]ven though fraud is generally confined to situations involving misrepresentations of fact, an expression of an intentionally false opinion on a matter of law may be actionable where a relationship of trust exists.”  Allen v. WestPoint-Pepperell, Inc., 945 F.2d 40, 45-46 (2d Cir. 1991) (citations omitted).

It is “well settled” that “fraud cannot be predicated upon misrepresentations of law or misrepresentations as to matters of law.”  Statements, and even misrepresentations, of law are generally regarded as opinions which cannot be relied upon absent special circumstances.

Carolina Casualty Insurance Co. v. Capital Trucking, Inc., 523 F. Supp.3d 661, 680 (S.D.N.Y. 2021) (quoting Singh v. NYCLT 2009-A Trust, 2016 WL 3962009, at *7 (S.D.N.Y. July 20, 2016), aff’d, 683 F. Appx. 76 (2d Cir. 2017)).

North Carolina

In North Carolina, “fraud cannot be based upon ignorance of the law.”  Avriett v. Avriett, 363 S.E.2d 875, 878 (N.C. App.), aff’d, 368 S.E.2d 377 (N.C. 1988) (per curiam).  “[I]gnorance of . . . legal effect” is not a basis for a fraud claim.  Biesecker v. Biesecker, 302 S.E.2d 826, 829 (N.C. App. 1983) (citations omitted).

Generally speaking, a party cannot attack the making of a contract on the basis of fraud where the proof regarding the misrepresentation or misstatement relates to a matter of law.  This is based primarily on the following related principles:  that everyone is equally capable of determining the law, is presumed to know the law and is bound to take notice of the law and, therefore, in legal contemplation, cannot be deceived by representations concerning the law or permitted to say he or she has been misled.

Dalton v. Dalton, 596 S.E.2d 331, 333 (N.C. App. 2004) (citations and quotation marks omitted).  Accord Lockerby v. Cross Point NC Partners, LLC, 2023 WL 4918359, at *6 (W.D.N.C. Aug. 1, 2023) (“In North Carolina, a plaintiff generally cannot claim that they were misled by a misrepresentation of law.”) (citation omitted); Cross v. Formativ Health Management, 439 F. Supp.3d 616, 627 (E.D.N.C. 2020) (a “party’s statement of a legal position or an assertion about its rights or position under the law is not an actionable misrepresentation”) (citations omitted).  Cf. Cross v. Ciox Health, LLC, 438 F. Supp.3d 572, 585 (E.D.N.C. 2020) (“a party’s statement of a legal position or an assertion about its rights or position under the law is not an actionable misrepresentation for purposes of a UDTPA claim”) (citations omitted).

North Dakota

The North Dakota Supreme Court weighed in on legal misrepresentations not being fraud a long time ago.  “[I]n so far as the action may be thought to be predicated upon a misrepresentation of law, it cannot be regarded as an action for deceit.”  Hellebust v. Bonde, 172 N.W. 812, 813 (N.D. 1919).  “The argument is the familiar one that both parties are presumed to know the law, or at least “ignorantia legis neminem excusat,” and that consequently no one is capable of being legally deceived or damaged by a misrepresentation of a matter of law.”  Id. at 812.  A century later the same court followed Hellebust and held, “[plaintiffs] are charged with knowledge of statutes and ordinances.  We conclude that a claim for deceit based on misrepresentation of law is barred as a matter of law.”  Arnegard v. Arnegard Township, 908 N.W.2d 737, 751 (N.D. 2018).  Accord Jacam Chemical Co. 2013, LLC v. Shepard, 101 F.4th 954, 968 (8th Cir. 2024) (“Generally, a misrepresentation of law is not actionable fraud in tort.”) (citation and quotation marks omitted).

Ohio

Ohio law likewise has endorsed the proposition fraud cannot lie for legal misrepresentations.  “[U]nder Ohio law, a representation of law is an opinion and cannot form the basis of an action for fraud in the absence of a fiduciary relationship.”  Armatas v. Haws, 110 N.E.3d 759, 763 (Ohio App. 2018) (citation omitted).  “It has been long held that, under Ohio law, a representation of law is an opinion and cannot form the basis of an action for fraud in the absence of a fiduciary relationship.”  Id.

Plaintiffs’ allegations of “fraud” essentially assert that the defendants somehow represented the loans to be “lawful”. . . .  However, under Ohio law, a representation of law is an opinion and cannot form the basis of an action for fraud in the absence of a fiduciary relationship.

Lynch v. Dial Finance Co. No. 1, Inc., 656 N.E.2d 714, 720 (Ohio App. 1995) (citing, inter alia, Aetna Insurance Co. v. Reed, 33 Ohio St. 283, 293-94 (1877)).  Accord Barnes v. Reserve Energy Exploration, 68 N.E.3d 133, 141 (Ohio App. 2016) (same); Bergmoser v. Smart Document Solutions, LLC, 268 F. Appx. 392, 395 (6th Cir. 2008) (A legal misrepresentation cannot form the basis of a fraud or intentional misrepresentation claim, as a matter of law.”); Avery v. Joint Township Dist. Memorial Hospital, 286 F. Appx 256, 267 (6th Cir. 2008) (“Ohio courts have determined that a representation of law amounts to an opinion and therefore cannot form the basis for a fraud claim unless there is a fiduciary relationship between the parties.”).

Oklahoma

In Oklahoma, “with limited exceptions, fraud cannot be predicated on misrepresentations of law or misrepresentations as to matters of law.”  First National Bank in Durant v. Honey Creek Entertainment Corp., 54 P.3d 100, 104 (Okla. 2002) (citations omitted).  “[A] misrepresentation of law affords no grounds of redress or relief on the theory that all men are supposed to know the law.”  Nesbitt v. Home Federal Savings & Loan Ass’n, 440 P.2d 738, 743 (Okla. 1968) (citation and quotation marks omitted).  An exception exists where the defendant claims a “superior” knowledge of the law.  Id.  Thus, Oklahoma “recognizes the rule that misrepresentations of law do not form the predicate for an action based on fraud.”  Ford Motor Credit Co. v. Milburn, 615 F.2d 892, 895 (10th Cir. 1980) (citing Nesbitt).

Oregon

Oregon seems to be all over the lot.  Sorensen v. Gardner, 334 P.2d 471 (Or. 1959), first recognized the general rule:

[I]t is argued that the misrepresentations alleged are mere expressions of opinion or representations of law and therefore not actionable. This may be true of [one] representation . . . but [another] representation . . . is one of fact.  With respect to the other charges in the complaint, it is a general rule that fraud cannot be predicated upon misrepresentations of law or misrepresentations as to matters of law.  Thus, misrepresentations concerning the legal effect of an instrument have been held to be not actionable.

Id. at 473 (citation omitted).  But Sorenson went on to hold, in accordance with Restatement §545, that the rule did not apply to “business transactions” where legal representations could be considered facts or “the legal consequences of facts.”  Id. at 474.  But, in Wochnick v. True, 356 P.2d 515, 518 (Or. 1960), decided shortly after  Sorenson, the traditional rule applied:

Plaintiff, in effect, is contending the legal rights bestowed upon her by the documents for which she traded were other than as represented. . . .  Therefore, the representation, if made, was a representation of opinion as to the legal effect of the documents in question, and she was not entitled to rely thereon.

Id. at 518.  See Travis v. Knappenberger, 87 F. Appx. 24, 26 (9th Cir. 2003) (because plaintiff “was aware of all the facts, . . . defendant’s statement . . . was a legal opinion” requiring summary judgment under Sorenson).

CompareDenison v. Brown, 2008 WL 483334, at *3 (D. Or. Feb. 19, 2008) (“[it] is well established that misrepresentations of the law are not actionable as fraud because statements of the law are considered merely opinions.”  (citation and quotation marks omitted); with Criqui v. Pearl Music Co., 599 P.2d 1177, 1179-80 (Or. App. 1979) (“The law no longer precludes actions based on fraudulent representations as to the law. Whether such a misrepresentation is actionable depends on the circumstances.”).

Pennsylvania

In addressing fraudulent concealment, the Supreme Court of Pennsylvania recently held:

[F]raudulent concealment, . . . ordinarily pertains to conduct on the part of the defendant which causes the plaintiff to relax his vigilance or deviate from his right of inquiry into the facts.  Generally, the misrepresentations relied on must be misrepresentations of fact and not misrepresentations of law since all are presumed to know the law.  This Court has never applied it to an assertion that the defendant misrepresented the current state of the law.

Johnson v. Wetzel, 238 A.3d 1172, 1181-82 (Pa. 2020) (citations, quotation marks, and footnote omitted) (emphasis original).  To find anything else, we had to go back a long way:

A representation of a rule of law unless made by one supposed to have expert knowledge of the special rule to one who is ignorant of the subject, is inoperative.  Except under such circumstances, the truth or falsehood of misrepresentations of law should not be relied upon.

A. P. Landis, Inc., v. Mellinger, 175 A. 745, 746 (Pa. Super. 1934) (citation and quotation marks omitted).

Puerto Rico

We found very little (and AI found nothing) on this subject for Puerto Rico.  Adrian v. Mesirow Financial Structured Settlements, LLC, 736 F. Supp.2d 404 (D.P.R. 2010), held that the plaintiff “cannot show that her reliance was reasonable because the alleged misrepresentation regarded a matter of law.”  Id. at 422.  But Adrian was applying South Carolina, rather than Puerto Rico, law.

Rhode Island

We found nothing in Rhode Island except a block quote from Restatement §525 containing the “misrepresentation of fact, opinion, intention or law” language in a case having nothing to do with allegations of legal misstatements.  French v. Isham, 801 F. Supp. 913, 921 (D.R.I. 1992).

South Carolina

In South Carolina “misrepresentations as to matters of law are not actionable.”  Carolina Chloride, Inc. v. Richland County, 714 S.E.2d 869, 874 (S.C. 2011).  “There is no liability for casual statements, representations as to matters of law, or matters which plaintiff could ascertain on his own in the exercise of due diligence.”  Isaac v. Onions, 915 S.E.2d 492, 497 (S.C. 2025) (quoting Quail Hill, LLC v. County of Richland, 692 S.E.2d 499, 508 (S.C. 2010).  Thus, “our courts have repeatedly recognized the general rule that fraud cannot be predicated on misrepresentations as to matters of law, much less mere mistakes of law.”  Anderson County v. Preston, 804 S.E.2d 282, 292 (S.C. App. 2017), vacated on procedural grounds, 831 S.E.2d 911 (S.C. 2019).

South Dakota

South Dakota law bars fraud claims based on alleged legal misstatements.

Plaintiff’s claim for negligence is premised on the allegation that a misrepresentation of law caused its damages.  [Plaintiff] cannot avoid that fact by relabeling the name of its claim.  Because misrepresentations of law are not actionable, the allegations show [a]n . . . insuperable bar to relief.

Total Auctions & Real Estate, LLC v. S. Dakota Dept. of Revenue & Regulation, 888 N.W.2d 577, 581-82 (S.D. 2016) (citation omitted).  The omitted citation was to Meyer v. Santema, 559 N.W.2d 251, 255 (S.D. 1997), which similarly held:

[Plaintiff] is presumed to know the law. . . .  [Defendant’s] misrepresentations concerned interpretation and implementation of a . . . matter of law − misrepresentations of law are not actionable.

Id. at 255 (citations omitted).

Tennessee

In Tennessee “a statement of law cannot provide the basis for an intentional misrepresentation claim, except under narrow circumstances.”  Adams v. Delk Industries, Inc., 2021 WL 354096, at *7 (M.D. Tenn. Feb. 2, 2021).  Boyce v. LPP Mortgage Ltd., 435 S.W.3d 758 (Tenn. App. 2013), held:

[M]isstatements as to the law do not qualify as material factual misrepresentations[.]  It is well settled that a claim of fraud . . . cannot generally be supported by proof of misstatements as to matters of law. . . .  The rule, which is in essence an application of the broader principle that fraud must rest on a misrepresentation of a matter of fact . . ., is based on the principle that everyone is equally capable of determining the law, is presumed to know the law and is bound to take notice of the law and, therefore, in legal contemplation, cannot be deceived by representations concerning the law or permitted to say he or she has been misled.

Id. at 773 (citation and quotation marks omitted).  The exceptions were “not applicable in this case.”  Id.  Accord Best Choice Roofing & Home Improvement, Inc. v. Best Choice Roofing Savannah, LLC, 446 F. Supp.3d 258, 276 (M.D. Tenn. 2020) (following Boyce).

Texas

Texas follows “the general rule that misrepresentations involving a point of law or the legal effect of a document will not support an action for fraud” with exceptions for fiduciaries and “superior knowledge.  Fina Supply, Inc. v. Abilene National Bank, 726 S.W.2d 537, 540 (Tex. 1987).  Thus, “[a] representation as to the legal effect of a document is regarded as a statement of opinion rather than of fact and will not ordinarily support an action for fraud.”  Id.

The general rule, often repeated, is that fraud cannot be predicated upon misrepresentations as to matters of law.  The reason usually given for the rule is that everyone is presumed to know the law, and hence has no right to rely upon representations made to him by another, and that such representations are to be treated as mere statements of opinions and not of fact.

Safety Casualty Co. v. McGee, 127 S.W.2d 176, 177 (Tex. Comm. 1939) (citations omitted) (cited in Fina).  Accord Cromwell v. Anadarko E & P Onshore, LLC, 676 S.W.3d 860, 877 (Tex. App. 2023) (“generally speaking, fraud cannot be predicated upon misrepresentations of law or misrepresentations as to matters of law”) (citations omitted), rev’d on other grounds, 716 S.W.3d 515 (Tex. 2025) (dismissal of fraud claim not appealed); Visa Inc. v. Sally Beauty Holdings, Inc., 651 S.W.3d 278, 311 (Tex. App. 2021) (“compliance status is a legal opinion, not a “material fact” upon which fraud can be based”) (citations and quotation marks omitted); Evans v. Dynasty Transportation, Inc., 133 S.W.3d 672, 677 (Tex. App. 2003) (“As a general rule, a misrepresentation as to a matter of law is to be regarded as merely an expression of opinion and will not support an action for fraud and deceit.”) (citations omitted); Taub v. Houston Pipeline Co., 75 S.W.3d 606, 621 (Tex. App. 2002) (“Generally, claims of fraud cannot arise from legal opinions.) (citations omitted).  There are many more older Texas appellate decisions to the same effect, some finding exceptions and some not.

Utah

Absent an exception, the proposition that “misrepresentations of law” do “not constitute remedial fraud, is “dispositive” under Utah law.  Gadd v. Olson, 685 P.2d 1041, 1044 (Utah 1984).  “[S]tatements of opinions as to the legal effect of contracts are not generally a proper basis for a claim of fraud.”  Berkeley Bank for Cooperatives v. Meibos, 607 P.2d 798, 805 (Utah 1980).  “It’s thus settled in Utah that, as a general rule, misrepresentations of law and opinions about the legal effect of contracts are not adequate bases for actionable fraud.”  England Logistics, Inc. v. Kelle’s Transport Service, LLC, 559 P.3d 45, 57 (Utah App. 2024) (citations and quotation marks omitted).

Vermont

In Winton v. Johnson & Dix Fuel Corp., 515 A.2d 371 (Vt. 1986), the court paid lip service to the rule that statements about legal issues cannot amount to fraud, but emphasized “strong qualifications”:

While representations about the status of the law were held at common law not to be actionable, and actionable only in limited circumstances in Vermont, the rule has long been subject to strong qualifications.  An important distinction must be made between representations of legal opinions and representations of fact relating to the law as it exists.

Id. at 373 (citations and footnote omitted).  Non-actionable statements “involve[] the legal meaning and effect of a statute, court ruling, document, instrument or other source of law.”  Id. at 374.  This holding was reiterated and expanded to the Vermont consumer protection statute in Webb v. Leclair, 933 A.2d 177, 182-82 (Vt. 2007).

Virginia

A century ago, the Virginia Supreme Court followed the “well-settled” proposition that:

A representation of what the law will or will not permit to be done is one on which the party to whom it is made has no right to rely; and if he does so it is his folly, and he cannot ask the law to relieve him from the consequences.  The truth or falsehood of such a representation can be decided by ordinary vigilance and attention. It is an opinion in regard to the law, and is always understood as such.  The law is presumed to be equally within the knowledge of all parties.

Hicks v. Wynn, 119 S.E. 133, 136-37 (Va. 1923) (citations and quotation marks omitted).

This appears still to be Virginia law.  See Phillips v. Wells Fargo Bank, N.A., 2018 WL 1946925, at *3 (E.D. Va. April 25, 2018) (“A misrepresentation of law does not qualify as a misrepresentation of a material fact.”); Batt v. Manchester Oaks Homeowners Ass’n, Inc., 2013 WL 1155519, at *5 (E.D. Va. March 19, 2013) (“such representations amounted, not to statements of fact, but either future promises or representations of law, neither of which constitutes an actionable basis for a fraud claim”); Wells Fargo Bank, National Ass’n v. Smith, 2010 WL 4622176, at *3 (E.D. Va. Nov. 5, 2010) (“A fraud claim cannot rest on a misstatement of the legal effect of a contract.”); Saunders v. Deutsche Bank National Trust Co., 2022 WL 20210733, at *2 (Va. Cir. 2022) (“a misunderstanding of the legal effect of a . . . filing is a misrepresentation of law, the knowledge of which is imputed to both parties, and not a misrepresentation of fact”) – all citing Hicks.

Washington

In Bonded Adjustment Co. v. Anderson, 57 P.2d 1046 (Wash. 1936), the Washington Supreme Court held:

This representation, if made, was one of law and not of fact and could not be a basis for an action for fraud.  The general rule is that misrepresentations as to the law, unaccompanied by any misrepresentation or concealment of the fact, cannot be made the basis of a fraud charge.

Id. at 1049 (citation and quotation marks omitted).  Accord Hobson v. Union Oil Co., 59 P.2d 929, 932 (Wash. 1936) (“the general rule is that misrepresentations of law cannot form the basis for an action for damages”; applying exception); Prest v. Adams, 252 P. 686, 688 (Wash. 1927) (“The general rule is that misrepresentations as to the law, unaccompanied by any misrepresentation or concealment of the fact, cannot be made the basis of a fraud charge.”).

That seems to be it, which seems strange.  None of these cases is indicated as being impaired, and we even checked the “distinguisheds” and found nothing on point.  We found a few stray references to the Restatement “or law” language in Washington cases:  Kaas v. Privette, 529 P.2d 23, 27 (Wash. App. 1974); Gunnarson v. Transamerica Life Insurance Co., 2014 WL 5782337, at *3 (W.D. Wash. Nov. 6, 2014); Asheim v. Pigeon Hole Parking, Inc., 175 F. Supp. 320, 328 (E.D. Wash. 1959), aff’d, 283 F.2d 288 (9th Cir. 1960) – but none of them involved allegations of legal misstatements, and none mentioned the above precedent.

We wonder if we’re missing something, but it seems like Washington does not allow fraud to be based on allegations of misrepresentation of law.

West Virginia

“Mistake of law alone will not, as a general rule, relieve one of the effect of his contract.”  Tolley v. Poteet, 57 S.E. 811, 812 (W. Va. 1907).  That’s it, except for rote references to the Restatement §525 “or law” language in opinions that have nothing to do with the legal restatement issue.  See Belville v. Ford Motor Co., 13 F. Supp. 3d 528, 545 n.20 (S.D.W. Va. 2014); United States v. Massenburg, 2004 WL 2370694, at *7 (S.D.W. Va. Oct. 21, 2004).  Whether West Virginia law remains the same after more than a century, we can’t say for sure.

Wisconsin

Bentley v. Fayas, 50 N.W.2d 404 (Wis. 1951), held:

The general principle of law applying to this type of case is . . . that fraud cannot be based upon misrepresentations as to matters of law or expressions of opinion as to what is the law governing a particular transaction. . . .  Pursuant to this principle it has been held that fraud cannot be predicated of misrepresentations as to the legal effect of a written instrument. . . .  Hence, fraud cannot be based on statements as to the law of insurance and the legal conditions on which the right of recovery on an insurance policy depends.  Our conclusion is that there is no liability . . . on a cause of action in tort based upon fraud and deceit.

Bentley v. Fayas, 50 N.W.2d 404, 408 (Wis. 1951) (citation and quotation marks omitted).  That’s been the law in Wisconsin ever since.  Suskey v. Davidoff, 87 N.W.2d 306, 310 (Wis. 1958) (“the claimed statement was with respect to the legal effect of the document, . . . and hence dealt with a matter of law rather than fact, and . . . [that] statement cannot be held to constitute actionable fraud”) (citations omitted); Nelson v. Taff, 499 N.W.2d 685, 687 (Wis. App. 1993) (“Misrepresentations of law are generally not actionable as fraud.  But there are exceptions” such as superior knowledge) (citation omitted); Ritchie v. Clappier, 326 N.W.2d 131, 133 (Wis. App. 1982) (“Misrepresentations of law are generally not actionable as fraud.”) (citation omitted); Radford Co. v. Ruan Transport Corp., 2009 WL 5216985, at *2 (E.D. Wis. Dec. 30, 2009) (“representations of law . . . as to what governs a particular transaction . . . are generally not actionable”) (citations omitted); Wojciechowski v. Amoco Oil Co., 483 F. Supp. 109, 114 (E.D. Wis. 1980) (“As a general rule in Wisconsin, fraud cannot be based upon misrepresentations of law.”) (citation omitted)

The Wisconsin Supreme Court acknowledged the “general rule” that when “the misrepresentation complained of [is] one of law . . . and therefore not the basis of an action” in Rusch v. Wald, 232 N.W. 875, 875 (Wis. 1930), but did not apply it to brokers’ fiduciary relationship with their clients.

Wyoming

Wyoming follows “the well-recognized rule that such statements [“misrepresentations as to matters of law”] relating to matters of law are not ordinarily actionable.”  State Farm Mutual Automobile Insurance Co. v. Petsch, 261 F.2d 331, 334 (10th Cir. 1958) (citing Burnett v. Taylor, 252 P. 790, 794 (Wyo. 1927) (“misrepresentations of matters of opinion and of law are not actionable”)).

*          *          *          *

As mentioned, we used an AI function designed to generate 50-state surveys.  It was only marginally useful, although it didn’t take very long to do.  In a couple of instances, it did produce something that our own analog research methods (utilizing key numbers and shepardizing what looked like the key cases) did not.  But on far more occasions (most notably Pennsylvania), our tried and true methods unearthed precedents that the AI tool completely missed, and in some cases they were the best precedents in the state.

Nor is the AI tool really ready for prime time.  It has no concept of judicial hierarchy, and doesn’t organize string citations by either court level or date.  It doesn’t provide page cites.  It doesn’t sort federal courts of appeals by state, and compounds that problem by not including the state from which such cases originated.  Where it doesn’t find much, AI repeats the same generalized statements over and over again for each state.  It doesn’t understand what Restatements are.

Perhaps worst, this AI tool is sycophantic, which causes it to include results as “favorable” that don’t really stand for the specific proposition at all.  All in all, our readers would not want to read what the AI program generated.

Photo of Eric Hudson

You’ve probably noticed there’s been a lot of soccer going on recently. We don’t purport to be experts on the “beautiful game,” but every four years we find ourselves riveted by a sport we don’t always watch and sometimes don’t understand. The expanded field of 48 teams generated lots of unexpected excitement, and we thoroughly enjoyed Cape Verde’s Cinderella run into the elimination round, the United States winning their group, the underdog performances from New Zealand, Qatar and Australia, and of course the good-natured Viking antics from the Norwegian team and fans.  

Unlike the world cup games that left us riveted, today’s decision is a bit of a mixed bag and leaves us feeling a little blah (maybe the finals on Sunday between Spain and Argentina will provide one last blast of excitement before we put our weeks-long soccer watching binge on the shelf until 2030). Despite thinking that we’ve seen the last of them, we continue to see cases involving pedicle screws. A few months ago we wrote about a Buckman preemption decision dismissing claims involving pedicle screws.  And today’s decision offers a new take—a lawsuit against the manufacturer of a surgical robot that assists surgeons in placing pedicle screws. Nalder v. Walsh, 2026 WL 1984254 (S.D. Miss. July 9, 2026).

The plaintiff underwent lumbar fusion surgery in which the surgeon utilized a surgical robot to place pedicle screws into the plaintiff’s back. After the surgery, the doctor told the plaintiff that the “robotic arm had malfunctioned and that the L5 right pedicle screw was drilled in the wrong location.” Id. at *1. On a return visit, the plaintiff asked the surgeon how the robot malfunctioned. The doctor told him that the robot “reprogrammed” itself onto an incorrect vertebra, and that caused the surgeon to misplace the screw. The surgeon then had to replace the screw in the correct location during the surgery. The plaintiff claimed to experience neurological defects in his right foot because of the screw misplacement. He filed a malpractice action against his surgeon and included claims against the robot manufacturer for strict liability and breach of warranty. The manufacturer moved to dismiss.

Defendant’s first argument was that the complaint relied on common law strict liability claims that are no longer recognized in Mississippi—they are controlled instead by the Mississippi Products Liability Act (“MPLA”). Despite the complaint’s assertion of common law claims that no longer exist in Mississippi, the court found that the allegations tracked the statute. With that and the acknowledgement by plaintiff in his opposition to the motion to dismiss that his claims were controlled by the MPLA, the court held that the allegations were sufficient to avoid wholesale dismissal. Id. at *2.

Moving on from the threshold question about the MPLA, the court then discussed the facts alleged in the complaint. There were two: (1) the allegations that the surgeon observed the robot’s malfunction and the surgeon blaming the robot for the screw misplacement; and (2) the FDA sent the manufacturer a warning letter six months before the surgery stating that the manufacturer failed to report certain reportable events and identifying five unreported events that suggested the robot device “malfunctioned (i.e, misplaced screws) while in use.” Id. at *4.

The court next looked to whether those allegations were sufficient to state design and manufacturing defect claims. At the outset, the court noted that the complaint did not identify “how the product deviated” from the manufacturer’s design or specifications, and that the complaint did not even “mention” an alternative feasible design—both requirements under the MPLA.  Id. at *4. Absent those, and given the basic requirements of Twombly/Iqbal, we read the decision with the expectation that dismissal would be up next. But in an unexpected curve worse than a Messi corner kick, the court referenced the Seven Circuit Bausch decision—which we’ve previously bashed for its misapplication of Twombly/Iqbal—resulting in plaintiff escaping dismissal in a manner more miraculous than Argentina’s dramatic comebacks against Egypt and England. The court cited to other federal court decisions dismissing claims under the MPLA, including Deese v. Immunex Corp., 2012 WL 463722 (S.D. Miss. Feb 13, 2012) (which we blogged about here), but the court held that the bare-bone factual allegations regarding the surgeon’s statement and the FDA letter were enough to save the claims from dismissal.   

Turning next to failure to warn, the defense argued that the complaint did not allege any facts supporting the failure to warn claim and that it did not plead elements of the learned intermediary rule. The court agreed. The complaint did not identify the warnings the defendant included, did not allege that the surgeon would not have used the device if a different warning had been given, and it did not identify what warning the plaintiff claimed should have been given. Absent those details, the court held that the failure to warn claim was not “factually plausible” and dismissed the claim. Id. at *6.

The court also dismissed plaintiff’s breach of warranty claims. It dismissed the implied warranty claim because plaintiff did not oppose dismissal. For the express warranty claim, the complaint did not meet the requirements under the MPLA that a plaintiff must allege “specific statements or representations” by the defendant. Id. Instead, plaintiff made only conclusory allegations that “failed to identify the express warranties or representations that were allegedly breached.” Id. Given that, the court dismissed the express warranty claim.

It is worth noting that the reference to the FDA letter—which is almost always raised by plaintiffs in an effort to support a warning claim—was used to support the design and manufacturing defect claims.  We think there’s a good argument that a failure to report claim doesn’t exist at all in Mississippi (as we blogged about in our 50 state survey), and that raises the question how the failure to report allegation can ultimately support a design or manufacturing defect claim.  That at least suggests the plaintiff may have a tough time getting past summary judgement. In the meantime we’ll hope to hear more inspiring goal calls by Andrés Cantor this weekend.

Photo of Lisa Baird

We’ve re-read Monsanto Co. v. Durnell, No. 24-1068, 609 U.S. ___, 2026 LX 336645, 2026 WL 1825691 (June 25, 2026) (“Durnell”), a few times over the past few weeks.  As Bexis noted in his quick-out-of-the gate (and great) analysis, there is a lot in there to use in our medical device preemption cases. 

The point is, just because Durnell involved Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”) preemption, please don’t just skim it and move on.

The primary reason why it deserves a spot in your regular preemption authorities rotation is because it extensively and directly relied on Riegel, and it had a lot of good things to say about the meaning of Riegel that will run counter to many arguments you see from the other side of the “v”. 

As the Supreme Court said, Riegel was instructive to its analysis in Durnell, a FIFRA preemption case, because “[i]n Riegel, the Court addressed the preemption clause in the Medical Device Amendments of 1976, which is nearly identical to FIFRA’s preemption clause.”  Durnell, 2026 U.S. LEXIS 2721 at *20 (emphasis added).  In addition:  Both the FDA (for medical devices and OTC drugs) and the EPA (for pesticides) analyze the safety of their regulated products before they can grant approval; both must ensure product labels are “neither false nor misleading”; and after approval, “the manufacturer is required to use that label and is prohibited from making any changes to the device or label” without additional federal approval.  Id.

For our purposes, just as the similarities between the express preemption clauses in the Medical Device Amendments and FIFRA made Riegel “dispositive” of the FIFRA preemption issue in Durnell, the similarities between the two should also make the holding in Durnell dispositive of Durnell-type arguments in your Medical Device Amendment express preemption mattersSee id. at *21 (Supreme Court recognizing that its Durnell “affects more that FIFRA” and applies to cases involving similar preemption provisions, like 21 U.S.C. 360k(a)).

Again: Don’t let good Supreme Court precedent go to waste!

A Durnell Recap

In Durnell, the plaintiff contended that even though the EPA had approved a pesticide’s label without a cancer warning, the manufacturer should have given a cancer warning, and was liable under state tort law for not doing so.  Id. at *6.

The Supreme Court readily found that claim preempted, because that “state tort claim would require [the manufacturer] to add a cancer warning to [the pesticide’s] label even though federal law require[d] [the manufacturer] to use the EPA-approved label without a cancer warning.”  Id. at *6-*7, *14-*15.  Thus, the state law requirement was “in addition to” and “different from” the manufacturer’s federal-law labeling obligations, and preempted.  Id. at *18.

The Supreme Court also shot down three arguments raised by the Durnell plaintiff in trying to avoid preemption.

First, the Durnell plaintiff argued that preemption did not apply because state and federal law were consistent—basically, that Plaintiff’s state law failure-to-warn claim and a “misbranding” provision in FIFRA both require “adequate warnings” that are not “false or misleading.”  Id. at *15, *22. 

That argument failed because it “operate[d] at far too high a level of generality.”   

Looking at only FIFRA’s general standard for misbranding rather than the specific requirements imposed under federal law would nullify FIFRA’s preemption clause and the uniformity that Congress sought for safety warnings on pesticide labels.

Id. at *22.

Although the majority did not explicitly discuss whether or how to state a parallel claim that survives preemption (and the dissent said Riegel never addressed this issue at all, id. at n.9 (Jackson, J. dissenting)), this “misbranding is too general” point is interesting.  It suggests that there must be a good amount of equivalence between the duty under federal law and the duty under state law.  See, e.g., Wolicki-Gables v. Arrow Int’l, Inc., 634 F.3d 1296, 1300 (11th Cir. 2011) (genuinely equivalent); Otis-Wisher v. Medtronic, Inc., 616 F. App’x 433, 434 (2d Cir. 2015) (identical). 

In any event—and this is key—regardless of what warnings the Durnell plaintiff believed should have been given over time, different or additional warnings flew in the face of the specific labeling requirements that the EPA actually had imposed in reviewing and approving specific label language.  Id. at *22.

Second, the Durnell plaintiff suggested that “the EPA-approved and EPA-required label” had “become misbranded over time due to new evidence.”  In essence, they argued that post-approval events had overtaken the EPA’s initial label approval, with new information rendering that label inadequate over time.  Id. at *25-28.  That argument also failed. 

Allowing a post-approval failure-to-warn claim as plaintiff suggested “would negate FIFRA’s express preemption clause, expose manufacturers to potentially massive tort liability for doing what EPA required them to do, and eviscerate the ‘uniformity’ of EPA’s labeling determinations.”  Id. at *28.  

Simply put, the plaintiff’s allegations about new information did not deprive the EPA’s original warning label determinations “of their preemptive force.”  Id. at *29.

Durnell also recognized that such arguments also “contravene” the Supreme Court’s Riegel decision. 

Similar to the EPA’s powers under FIFRA, the FDA is authorized to “withdraw premarket approval for a medical device based on ‘newly reported data or existing information’” and is required to do so if it newly determines the device is unsafe in ineffective.  Id. at *28-29 (quoting Riegel, 552 U.S. at 319).  Despite that federal power to reassess new data and to change its approval decision, the Supreme Court in Riegel still concluded that the in-effect premarket approval imposed federal requirements that preempted state tort suits.  Id. at *29 (citing Riegel, 552 U.S. at 322-23). 

A third, and related, argument was one of policy.  The Durnell plaintiff suggested that the regulatory response would inevitably lag the development of post-approval safety information and thus federal regulation and preemption should step aside and allow that gap to be addressed through plaintiff-driven state tort lawsuits.  Id. at *30. 

The Supreme Court was not swayed.  Not only did its textual analysis of “in addition to” and “different from” express preemption provisions preclude such claims [id. at *18], imposing liability also was unnecessary given regulatory authority.  Similar to what is required of medical device manufacturers, FIFRA requires manufacturers to “apprise EPA of new information ‘regarding unreasonable adverse effects’ of their pesticides”; it allows the EPA to require more information, conduct new scientific analyses, and review third party petitions to modify or cancel a pesticide’s approval”; and it has other mechanisms for outsiders to bring new safety information to the regulator’s attention as well.  Id. at *30-31. 

In other words, the “comprehensive regulatory regime” provides EPA with “a variety of tools to learn of and address new safety information” but in an event, “as a matter of law, state tort law may not impose labeling requirements ‘in addition to’ or ‘different from’ federal requirements imposed under FIFRA.”  Id. at *31.

Using Durnell In Medical Device Preemption Cases

The Supreme Court itself said that Riegel controlled Durnell, and that Durnell would affect more than FIFRA cases, so there is no mystery about whether Durnell matters to the issues in our sandbox.  It does; the Court itself says so.

But more than that, doesn’t Durnell actually wipe out a lot of the parallel-claim nonsense in the medical device sphere?

Think about Bausch v. Stryker Corp., 630 F.3d 546, 554-55 (7th Cir. 2010), in which the Seventh Circuit rejected the defense arguments that Quality System Regulations (QSRs) and CGMPs are “too general to allow juries to enforce them.” But Durnell just said that “misbranding” operated at “far too high a level of generality,” and we would argue that Durnell‘s conclusion carries through to QSRs and CGMPs as well.

Think also about Stengel v. Medtronic Inc., 704 F.3d 1224 (9th Cir. 2013).  Wasn’t that a Durnell-style post-sale duty to warn claim?

In particular, the Stengel plaintiff’s contention, as proposed in an amended complaint, was that the device manufacturer had a federal law “continuing duty to monitor the product after pre-market approval” and a failure to comply with that federal duty breached the “duty to use reasonable care” under Arizona negligence law.  Id. at 1232.  Sorry, but that is a lot of “too high a level of generality” on both the federal requirement side and the state requirement side.

Then there is Stengel’s stated rationale for finding plaintiff’s claim not preempted: “Arizona state law has long been concerned with the protection of consumers from harm caused by manufacturers’ unreasonable behavior.”  Id. at 1233. 

Durnell shut that down, recognizing that the regulatory authority afforded the EPA under FIFRA was more than well-equipped to address safety concerns—and if anything, the FDA’s regulatory powers are even greater where PMA medical devices are concerned.   

Of course, the Stengel majority also stepped in to re-work the plaintiff’s claim by purporting to identify a more “precise parallel”—namely the federal requirement to report adverse events to the FDA and a state-law duty to warn.  See id. at 1233.

Judge Watford, in his concurrence, recognized that this gloss meant the plaintiff would “ultimately have to prove that” the new and different information—not included in the federally-required warning label—would have had to reach Mr. Stengel’s doctors, and resulted in a different medical treatment decision that would have prevent his injuries.

Setting apart the other reasons why Stengel is nonsense (see, e.g., here and here), doesn’t this run squarely into the most fundamental point in DurnellDurnell looked past all the arguments about new and different information developed post-approval, and recognized this one fundamental truth: A different warning is a different warning is a different warning. 

If the federal regulator didn’t require that warning to be given, then state law cannot require otherwise, full stop. 

Photo of Stephen McConnell

This makes two weeks in a row with vaccine cases. Last week we discussed yet another Constitutional challenge against mandatory vaccination. This week we look at Nguyen v. Sec’y of Health and Human Services, 2026 U.S. Claims LEXIS 1650 (U.S. Ct. Fed. Claims June 22, 2026), a federal circuit Vaccine Act compensation case.  Such cases are infrequently interesting, but this one contains one of the most thorough take-downs of case reports as poor quality scientific evidence that you will likely ever see.  

The claim in Nguyen, which was rejected, was that a hepatitis B vaccine caused the plaintiff to suffer from a neurological condition, Guillain-Barré syndrome (GBS). Because GBS was not listed on the relevant Vaccine Table, this was a non-table injury case (duh), and thus the plaintiff had to satisfy “traditional causation standards” (not so duh). More specifically, the plaintiff needed to present preponderant evidence of (1) a medical theory causally connecting the vaccination and the injury; (2) a logical sequence of cause and effect; and (3) a temporal relationship between vaccination and injury.  The court accepted that the plaintiff met the requirement of temporal relationship (the GBS hit the plaintiff between two and five weeks after the vaccination).  So that’s one out of the three requirements being met.  But that’s it. And, riffing off the old Meatloaf song, one of three is bad. 

The court did not see a logical cause and effect scenario, so that was bad news for the plaintiff — bad enough to end the case.  But the court devoted most of its analysis to the medical causation theory, and there the plaintiff had serious problems.  

First, the plaintiff proffered a neurological expert with fine qualifications in the field of neurology, but the real issue here was immunology. The mismatch between expertise and the issue at hand was viewed by the court as a “detriment” to the plaintiff’s case.  The defense expert, too, was a neurologist, not immunologist. That, too, is a detriment, but it is the plaintiff, not the defendant, who “bears the burden of presenting a persuasive case.”

Then the Nguyen court carefully analyzed both the case law and epidemiology on vaccination causation of GBS. The plaintiff’s proposed biological mechanism was “molecular mimicry,” which had support that could be characterized as frail at best.  The epi studies either involved a different vaccine or reliance on an unreliable database (described in another case as a “stocked pond”), and discredited experts. At most, the plaintiff could claim a standoff on epidemiology – again, that is not enough to meet the plaintiff’s burden. 

That leaves us with case reports and case series.  This is the part of the case that will most gladden the flinty hearts of defense hacks. A case report equals mere anecdote, and “anecdote” is not the singular of “data.”  Other Federal Circuit cases considering vaccine claims have “endorsed, albeit indirectly, a view that case reports merit little weight.” The Nguyen court does a good job of collecting many cases discounting case reports, both in and out (e.g., the Abilify MDL) of the vaccine program. Then, “in accord with these judicial authorities,” the Nguyen court declined to give the plaintiff’s “case reports much, if any weight.” Even beyond the general principle that case reports are weak, the particular ones cited by the plaintiff were especially off the mark. 

The Nguyen court directly confronted another case that came to a contrary result. The “primary difference” between the cases was the weight of case reports, and the Nguyen court held that the weight was too little to permit the plaintiff to proceed with the vaccine compensation claim. Naturally, we side with the Nguyen case and give a bitter side-eye to the more lenient, permissive, pro-plaintiff case. 

For any case you work on in which the evidentiary value of case reports is an issue, Nguyen is worth review and citation.

Photo of Michelle Yeary

There’s an old joke about a guy who keeps banging his head against the wall. When asked why, he says: Because it feels so good when I stop. That’s roughly how we feel about watching defendants in medical device cases make preemption arguments under the shadow of Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996). The head-banging is painful. It never really stops. But somebody has to keep doing it, because the wall eventually has to come down.

The latest occasion for this exercise is Dyer v. Coloplast Corp., 2026 WL 1906706 (M.D. Fla. July 2, 2026) — a pelvic mesh case in which the defendant lost its preemption arguments on summary judgment. We are not happy about it. We are, however, not surprised. And we think the defendant was right to try, and should keep trying, because Lohr is a flawed decision and we’ve said so here for years.

Plaintiff underwent pelvic floor reconstructive surgery during which a surgeon implanted defendant’s mesh — an §510(k)-cleared Class II medical device — to treat stress urinary incontinence. Dyer, 2026 WL 1906706, at *1. Plaintiff developed pelvic, groin, and lower extremity pain, was diagnosed with neuralgias, and underwent two additional surgeries. Id. She sued the manufacturer for negligence, strict liability design defect, and strict liability failure to warn, and also sought punitive damages under Florida law. Id.

The defendant moved for summary judgment on several grounds—most notably that plaintiff’s design defect claims were impliedly preempted because, pursuant to FDA regulations it could not unilaterally change the mesh’s design without going through the §510(k) process. Id. Before deciding the impossibility preemption issue, the court noted the elephant that has been in the room for thirty years — the Supreme Court’s ruling in Lohr that §360k does not expressly preempt state-law design defect claims against §510(k)-cleared devices. Id. at *2. Lohr has been in our crosshairs for a long time, and not just because it goes against defendants. It is a jurisprudential mess. A fragmented plurality opinion whose central reasoning has been chipped away, overruled, or repudiated by nearly every subsequent Supreme Court decision to touch it.

We’ve laid out the case against Lohr in detail several times.  The short version: Lohr‘s anti-preemptive reasoning rested on (a) the presumption against preemption in express preemption cases; (b) deference to an FDA regulation (21 C.F.R. § 808.1(d)) restricting the preemptive scope of §360k(a); and (c) the Court’s gestalt view that Congress could not have intended to bar most tort relief for injured patients. Every one of those foundations has since been kicked out from under it.

So yes, Lohr controls on the express preemption issue for §510(k)-cleared devices. But that is a wall that needs to be brought down. The way to bring it down is to get a well-built record before a court willing to send the issue up, and to keep the issue alive and preserved in every case until the Supreme Court takes it.

In the meantime, the implied preemption argument is valid. It just needs to be paired with a common-law argument that the court in Dyer never addressed. The court rejected defendant’s implied preemption argument finding that the manufacturer “had complete and independent control over the [mesh’s] design before it sought §510(k) clearance for the device,” and therefore “[i]t was not impossible to simultaneously comply with federal and state law.” Id. at *3 (emphasis added, citations omitted).

But generally speaking state product liability law requires a finding that a product is defective when it leaves the defendant’s possession, not at some earlier time. The design defect theory the Dyer court allowed to survive is premised not on what the mesh was when it left defendant’s control post-clearance, but on what it should have looked like before it was ever submitted to the FDA for clearance. In other words — you could have designed it differently before you ever went to the FDA. Therefore, no impossibility. Therefore, no preemption.

But that reasoning has a common-law problem. The product liability claim is not against the defendant’s hypothetical, never-manufactured alternative design from years before FDA submission. It is against the device as actually sold. At the time of sale — indeed, at the time of submission — the device’s design was subject to federal clearance requirements. A state tort judgment holding that the design was defective is a judgment that the defendant should have done something different. What it should have done, according to the plaintiff’s theory, is submit a different design to the FDA. That is the very essence of a “stop selling” or “never start selling” claim that the Supreme Court held preempted in Mutual Pharmaceutical Co. v. Bartlett, 570 U.S. 472 (2013). Bartlett‘s logic applies here with full force. If the only way to comply with the state-law duty is not to have marketed the product in its FDA-cleared form, then complying with state law would have required federal regulatory action — the submission of a different §510(k) — that the defendant could not independently accomplish.

None of this analysis was in the opinion, but it should be in the next motion, and the next, and the one after that.

While the preemption ruling is probably our biggest problem with Dyer, it isn’t our only one. The failure to warn ruling illustrates a recurring problem. The IFU warned of pain, neuromuscular symptoms, chronic complications, and the need for revision surgery – the very injuries plaintiff claims. Dyer at *4. But the court let the claim proceed anyway, because plaintiff’s expert said the warning should also have included comparative risk data comparing transobturator slings with retropubic slings. Id. at *5.

This is the classic no-win warning game. No matter how comprehensive the IFU, some expert can always find something more that allegedly should have been said. The information that plaintiff says was missing here — comparative complication rates between sling types — has never been held necessary to an adequate warning by any Florida appellate court. The two cases the court cited are federal district court cases, neither of which is binding. Yet a Florida product liability defendant is now going to trial on a warning claim premised on a duty that Florida’s own courts have never recognized.

This is a textbook Erie problem. Federal courts sitting in diversity are supposed to apply existing state tort law, not expand it to include duties no state appellate court has ever imposed. Telling a physician that a transobturator sling carries a different risk profile than a retropubic sling is not a warning about potential harmful consequences — it is a comparative marketing disclosure. Florida has never required that.

One piece of good news. The court granted summary judgment against punitive damages. Id. at *7-8. Under Florida law, a plaintiff seeking punitive damages must show by clear and convincing evidence that the defendant was personally guilty of intentional misconduct or gross negligence — the latter defined as conduct “so reckless or wanting in care that it constituted a conscious disregard or indifference to the life, safety, or rights of persons exposed to such conduct.” Fla. Stat. § 768.72(2)(b). The court quoted the observation from Tesla, Inc. v. Banner, 411 So. 3d 1, 5 (Fla. 4th DCA 2025), that “[i]t would appear that the Florida Supreme Court has all but eliminated punitive damage awards in products liability cases.” Dyer, at *7. Plaintiff, whose response brief simply recycled her design defect and failure to warn arguments, never came close to meeting that standard. Summary judgment on punitives granted. Id. at *8.

We will take our wins where we can get them.

The defendant in Dyer lost the battles that almost every defendant in a §510(k) medical device case loses. That is the current state of play under Lohr‘s long shadow. But the shadow is not permanent. The jurisprudential ground beneath Lohr has been eroding for years. The express preemption argument, the properly-framed implied preemption argument paired with a state tort law defect-at-sale rule and Bartlett‘s stop-selling logic, and the Erie objection to court-created comparative warning duties — these are all worth pursuing, on the right record, in the right court. Keep banging. The wall will come down.

Photo of Bexis

Late last year, when we were putting together our massive post that collected and categorized every case that had ever judicially noticed an FDA document, we ran across the intriguing proposition that in deciding Rule 12 pleading-based motions, “allegations in a complaint are not credited where contradicted by judicially noticeable documents.”  We cited several appellate decisions for that principle.  The most recent one, Fuqua v. Santa Fe County Sheriff’s Office, 157 F.4th 1288 (10th Cir. 2025), stated:

The general rule prohibiting courts from considering evidence outside the complaint on a motion to dismiss has an[] exception:  matters of which a court may take judicial notice.  Judicial notice allows the court to accept a matter as proved without requiring the party to offer evidence of it.  And taking judicial notice precludes a party from introducing contrary evidence and, in effect, directs a verdict against him as to the fact noticed.

Id. at 1298 (citations and quotation marks omitted).  Fuqua cited a Supreme Court case for this point, Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007).  The Supreme Court held in that case, that in adjudicating Rule 12(b)(6) motions, “courts must consider the complaint in its entirety, as well as other sources courts ordinarily examine” such as “matters of which a court may take judicial notice.”  Id. at 322.

Other cases for this proposition include Sprewell v. Golden State Warriors, 266 F.3d 979 (9th Cir. 2001), affirming that in the 12(b)(6) context, courts “need not . . . accept as true allegations that contradict matters properly subject to judicial notice” or that “are merely conclusory, unwarranted deductions of fact, or unreasonable inferences.”  Id. at 988 (citations omitted).  The Sprewell decision has been particularly influential and has been followed by several other Ninth Circuit decisions.  Readers of this post will notice a disproportionately high percentage of the cases discussed below are from Ninth Circuit district courts.

For additional appellate authority supporting the general proposition that judicial notice trumps contrary pleadings, see Jeffery v. City of New York, 113 F.4th 176, 179 (2d Cir. 2024) (affirming dismissal when considering“ all matters of proper judicial notice”) (citation and quotation marks omitted); Secured Mail Solutions LLC v. Universal Wilde, Inc., 873 F.3d 905, 913 (Fed. Cir. 2017) (“[i]n ruling on a 12(b)(6) motion, a court need not accept as true allegations that contradict matters properly subject to judicial notice”) (citation and quotation marks omitted); Clark v. Stone, 998 F.3d 287, 298 (6th Cir. 2021) (“this court may take judicial notice of public records, and we are not required to accept as true factual allegations that are contradicted by those records”) (citation omitted); Massey v. Ojaniit, 759 F.3d 343, 353 (4th Cir. 2014) (courts “need not accept allegations that contradict matters properly subject to judicial notice”) (citation and quotation marks omitted); Kaempe v. Myers, 367 F.3d 958, 963 (D.C. Cir. 2004) (“Nor must we accept as true the complaint’s factual allegations insofar as they contradict . . . matters subject to judicial notice”) (citation omitted); Gupta v. Wipro Ltd., 749 F. Appx. 94, 97 (3d Cir. 2018) (“Although we generally must accept as true the complaint’s factual allegations, this requirement does not apply when the allegations are contradicted by . . . matters subject to judicial notice.”) (citation and quotation marks omitted).

We decided to look for cases that apply the general proposition that courts need not accept as true allegations refuted by matters subject to judicial notice in the specific context of prescription medical product liability litigation.  One such case is Plumlee v. Pfizer, Inc., 2014 WL 4275519 (N.D. Cal. Aug. 29, 2014), where the court took judicial notice of a drug’s FDA-approved labeling and certain changes to that labeling that also went through proper FDA regulatory channels.  Id. at *4 & n.2.  The court also took judicial notice of the existence of “dozens of exhibits submitted by Defendant” that “directly contradict Plaintiff’s claim.”  Id. at 8.  Those exhibits established that, contrary to the plaintiff’s allegations, she could not, as a “reasonable consumer,” have been “ignorant” of the issue she belatedly sought to litigate after the expiration of the statute of limitations.  Id. at *8.

On appeal, the Ninth Circuit affirmed.

[T]he district court took judicial notice of an extensive record of documents − all publicly available during the relevant limitations periods − which discussed [the efficacy issues raised by plaintiff’s complaint]. The district court did not err in taking judicial notice of these documents.  The judicially noticed documents either identified [the drug] specifically or referred to antidepressants generally. . . . Therefore, the district court properly rejected [plaintiff’s] allegation that no information questioning [the drug’s] efficacy existed within the three- and four-year limitations periods. . . to which a reasonably diligent consumer would have been exposed.

Plumlee v. Pfizer, Inc., 664 F. Appx. 651, 653-54 (9th Cir. 2016).

Chapman v. Abbott Laboratories, 930 F. Supp.2d 1321 (M.D. Fla. 2013), reached a similar result.  In Chapman the plaintiff’s allegations about the drug’s warnings were directly contradicted by its FDA-approved labeling, which was subject to judicial notice.

[Plaintiff’s] claim is squarely contradicted by the . . . judicially-noticed drug label that does contain warnings. . . .  This conflict renders implausible the failure to warn theory as currently pled in [plaintiff’s] strict liability and negligence counts. . . .  [It is] clear that the overarching theme of [plaintiff’s] case is failure to warn, as evidenced by [plaintiff’s] counsel’s summary of the action in his response to the motion to dismiss. . . .   Accordingly, the Court will grant the motion to dismiss insofar as it seeks dismissal of the strict liability and negligence counts.

Id. at 1323-24 (citation omitted).

Another example is De La Paz v. Bayer Healthcare LLC, 159 F. Supp.3d 1085 (N.D. Cal. 2016).  Relying on judicially noticed FDA enforcement materials (Forms 483) the court dismissed the plaintiff’s manufacturing defect claims because they misconstrued the contents of those documents:

[T]o escape implied preemption [plaintiff] must allege that the irregularities documented in the Form 483s resulted in a manufacturing defect that caused her injuries. . . .  [Plaintiff] has failed to allege such a manufacturing defect.

The complaint offers no description of the “non-conforming material” used in manufacturing the device, or how the use of that material caused a defect in the product itself.  In fact, the Form 483 indicated that [defendant’s] contract manufacturer used the “non-conforming material” in a validation protocol, not in the actual manufacture of the product.  Moreover, the report indicated that the manufacturer had erred by failing to adequately document the disposition of that material, not by using the material itself.  [Plaintiff] has provided no basis for concluding that the failure to document the disposition of non-conforming material in a validation protocol caused a manufacturing defect in any . . . device.

Id. at 1094-95 (citations omitted).  See also Id. at 1096, 1098 (additional dismissals of failure to train and express warranty claims due to contradiction with judicially noticed FDA documents).

Likewise, in Trisvan v. Heyman, 305 F. Supp.3d 381 (E.D.N.Y. 2018), the plaintiff alleged – falsely – “that there were no warnings about the relevant side-effects” with the defendant’s drug.  Id. at 399 (emphasis original).  Since the defendant’s judicially noticed warnings (and the Physician’s Desk Reference) belied that allegation, it was ignored and the aspect of the plaintiff’s complaint was dismissed:

In contrast to most other failure to warn cases, the adequacy of the warning in this action turns on its mere existence.  Defendants, however, have offered FDA-approved labels as evidence of warnings provided to physicians contemporaneous with or predating Plaintiff’s use. . . .  At the very least, these FDA labels list [specific warnings omitted].  Accordingly, Plaintiff’s failure to warn claims based on a lack of any warnings are dismissed with prejudice.

Id. at 400 (citations omitted).  Accord Trisvan v. Heyman, 2018 WL 6573434, at *4-5 (E.D.N.Y. Dec. 13, 2018) (second dismissal for “allegations in a complaint that contradict or are inconsistent with judicially-noticed facts”) (footnote omitted).

In Carter v. Amgen, Inc., 2015 WL 13388039 (C.D. Cal. July 16, 2015), aff’d, 682 F. Appx. 620 (9th Cir. 2017), plaintiff repeatedly alleged, in conclusory function, that the relevant use of a drug was “contraindicated.  Id. at 6.  “[J]udicially noticed FDA labels” established that these allegations were untrue, and the claim was dismissed:

[T]he contraindicated allegation is directly contradicted by the FDA-approved labels that the Court has judicially noticed. . . .  The labels each contain a section entitled “Contraindications”. . . .  [discussion of labeled contraindications omitted]  Thus, the Court need not accept as true the allegation that [the drug] was “contraindicated” for [decedent’s] use of the drug because the judicially noticed labels demonstrate that the allegation blatantly false.

Id. (citations and quotation marks omitted).

The same result occurred in Becker v. Cephalon, Inc., 2015 WL 5472311 (S.D.N.Y. Sept. 15, 2015).  Plaintiff’s warning-related allegations were “squarely contradicted” by the drug’s judicially noticed labeling, requiring their dismissal:

While a court must generally accept a plaintiff’s factual allegations as true in evaluating a motion to dismiss, it need not accept as true allegations in a complaint that contradict or are inconsistent with judicially-noticed facts.  Plaintiff’s allegations that [defendant] failed to warn of the risk [at issue] when taking [the drug] . . . are squarely contradicted by the [drug’s] label. . . .  Because all of the alleged side effects described by Plaintiff are specifically indicated as potential side effects in the drug’s package insert, . . . Plaintiff’s strict liability and negligence products liability claims based on a failure to warn theory are foreclosed and must be dismissed.

Id. at *5-6 (citations and quotation marks omitted).

Those decisions are hardly all the examples we found of contradictions with judicially noticed material resulting in Rule 12 dismissal.  Here are a bunch of other cases where FDA materials or other unimpeachable documents concerning FDA regulated products were judicially noticed and resulted in dismissal of claims, despite contrary pleaded allegations.  Govea v. Medtronic, Inc., 2025 WL 3467214, at *13 (C.D. Cal. Nov. 26, 2025) (judicially noticed FDA device approval establishes its intended uses; plaintiff’s claim of off-label promotion is dismissed because it concerned a labeled use); Brock v. City of Bellingham, 2025 WL 254725, at *5 (W.D. Wash. Jan. 21, 2025) (judicially noticing FDA COVID vaccine emergency use approvals; “[g]iven the judicially noticeable facts . . ., the Court concludes that the . . . vaccine available to Plaintiffs was not an ‘investigational drug’ at any time relevant to Plaintiffs’ claims”); Argueta v. Walgreens Co., 760 F. Supp.3d 1028, 1038 (E.D. Cal. 2024) (complaint dismissed where court took judicial notice that the defendant’s product “is indeed a drug approved for the treatment” of the relevant condition); Curtis v. PeaceHealth, 2024 WL 248719, at *2 (W.D. Wash. Jan. 23, 2024) (same as prior Curtis holding), aff’d, 154 F.4th 678 (9th Cir. 2025); Curtis v. Inslee, 709 F. Supp.3d 1257, 1265 (W.D. Wash. 2023) (The COVID vaccine’s status “is accurately and readily determined from the FDA’s approval and CDC’s explanation,” which “are sources whose accuracy cannot be reasonably questioned”), aff’d, 154 F.4th 678 (9th Cir. 2025); Leake v. Raytheon Technologies Corp., 2023 WL 2242857, at *1 n.2 (D. Ariz. Feb. 27, 2023) (judicially noticed FDA information established that allegation of a product recall was “demonstrably false”), aff’d, 2024 WL 1854287 (9th Cir. April 29, 2024); Morris v. Sun Pharma Global, Inc., 2021 WL 3913191, at *3 (C.D. Cal. May 13, 2021) (allegation that defendant was a drug “manufacturer” contradicted by judicially noticed FDA document listing defendant as a “distributor”; “[a]ll of Plaintiff’s allegations based on negligence relate to the manufacturing, not the distribution, of [the drug]”, so “Plaintiff fails to state a negligence claim”); Gioia v. Janssen Pharmaceuticals, 2021 WL 602683, at *4 (E.D.N.Y. Feb. 16, 2021) (judicial notice taken of drug labeling; “plaintiff’s conclusory allegations coupled with plaintiff’s allegations of suffering from the very side effects of which defendant warns, require dismissal of plaintiff’s claim”); Dye v. Covidien LP, 470 F. Supp.3d 1329, 1341 (S.D. Fla. 2020) (judicial notice taken of FDA-approved device instructions for use; “[c]learly, the IFU contradicts all of Plaintiff’s allegations”); Marroquin v. Pfizer, Inc., 367 F. Supp.3d 1152, 1163 & n.5 (E.D. Cal. 2019) (warning claims dismissed as inconsistent with judicially noticed drug label); Lifeway Foods, Inc. v. Millenium Products, Inc., 2016 WL 7336721, at *2 (C.D. Cal. Dec. 14, 2016) (non-prescription medical product case; judicially noticed FDA letters; “this Court . . . will not blindly accept allegations which are directly contradicted by evidence subject to judicial notice”); Porter v. Wetzel, 2012 WL 4442792, at *5 (Mag. W.D. Pa. Aug. 24, 2012) (judicial notice of FDA approval established that, contrary to the complaint, plaintiff received appropriate medical care), adopted, 2012 WL 4378116 (W.D. Pa. Sept. 25, 2012); In re Bayer Corp. Combination Aspirin Products Marketing & Sales Practices Litigation, 701 F. Supp.2d 356, 367-68 (E.D.N.Y. 2010) (allegations contrary to judicially noticed FDA documents disregarded; “[a]lthough . . . a motion to dismiss . . . tak[es] all the allegations as true . . ., the court is not required to reason in a vacuum”).

As our earlier post demonstrated, many types of FDA materials have properly been the subject of judicial notice.  To the extent that a complaint makes factually false allegations that defense counsel can refute by judicially noticeable FDA documents, these allegations can be disregarded for purposes of otherwise pleadings-based motions under Rule 12.  Successfully doing so can be of great value to our clients, which are thereby spared the expense and bother of discovery that waiting for summary judgment would otherwise require.

Photo of Bexis

Today’s guest post is by Kevin Hara, of Reed Smith, who is pinch-hitting for Steve Boranian. His post today discusses the Texas Supreme Court’s procedural reversal of a lower court’s refusal to hear an interlocutory appeal concerning application of a Texas distributor immunity statute arising in the context of an FDA-regulated drug. The distributor’s motion to dismiss had been denied by the lower court’s creation of a “product liability” limitation on the statute that was contrary to the statute’s express terms. As always, our guest posters should receive all the credit (and any blame) for their writings.

**********

It is an honor to pinch-hit for a great friend and mentor, one of the regular contributors to this esteemed blog who is enjoying a much-deserved respite.  As readers of this blog are aware, Plaintiffs and their attorneys are relentlessly seek to circumvent limitations on defendants’ liability, whether through creative pleading, trying to categorize the learned intermediary rule as an affirmative defense (it is not), pleading around defenses like the statute of limitations and preemption, blatant forum shopping—a plaintiffs’ playbook favorite—or in today’s case, seeking to evade the plain language of a Texas statute that limits the liability of non-manufacturing sellers. See Tex. Civ. Prac. & Rem. Code § 82.003. (“Section 82.003”).

The Texas Supreme Court recently issued an important procedural decision granting interlocutory review for a “substantial ground for difference of opinion” as to the interpretation of Section 82.003 that will potentially eliminate liability for the distributor in this featured action and other non-manufacturing sellers in the future.  That is good news, because Texas has often been problematic for product liability defendants, as the jurisdiction that invented the heeding presumption (which Texas thankfully no longer applies to prescription medical products), and a very late (if relatively enthusiastic) adopter of the learned intermediary rule.

In McKesson Medical-Surgical Inc. v. Cleveland, No. 26-0005, 2026 Tex. LEXIS 654, at *1-2 (Tex. June 26, 2026), the plaintiff died after visiting a medical spa, allegedly as a result of an infusion containing Total Parenteral Nutrition (“TPN”) electrolytes, an FDA-regulated drug that is administered intravenously to persons with impaired digestive systems due to medical conditions that inhibit their ability to process food and absorb nutrients.

The decedent’s relatives filed suit in Texas state court against the spa and the distributor of the TPN electrolytes; the latter moved to dismiss under Section 82.003.  This statute provides that “[a] seller that did not manufacture a product is not liable for harm caused to the claimant by that product unless the claimant proves” one of seven possible exceptions, including the types of involvement—inter alia, product design, warnings, alterations, express warranties, or knowledge of pre-existing product defects—that are not typical of distributors that act as conduits for supplying pharmaceuticals and medical devices in their original form.  See Section 82.003(a)(1)-(7).  Many states have similar “sealed package” statutes designed to insulate non-manufacturing sellers from liability.  This is sound policy because distributors (often named to defeat diversity) generally have no input or control over the design, manufacture, or warnings pertaining to such products.  Nor would they have knowledge of any alleged defects.  Therefore, statutes analogous to Section 82.003(a) are an important part of the arsenal in defending product liability actions as Bexis detailed here.

The plain language of the statute precludes liability against the distributor of the TPN electrolytes unless the plaintiffs establish one of the enumerated exceptions, and one would think that would be the end of the story.  If only things were that easy.  Unfortunately, that unambiguous language was not enough—at least for now.  Plaintiffs argued that the statute “applie[d] only to product liability actions,” not to their claim, simply because they chose not to allege that the “TPN electrolytes were defective.”  Rather, they contended that the distributor negligently created “an online portal” allowing an unlicensed purchaser to order TPN electrolytes for shipment to the spa.  Cleveland, 2026 Tex. LEXIS 654, at *2-3.  Notably, the statute contains no product liability limitation, nor is the “negligence” argument one of the seven exceptions to Section 82.003(a).

However, this atextual limitation was enough for the trial court to deny the distributor’s motion to dismiss, agreeing that Section 82.003(a) “[did] not apply to sellers, . . ., in cases that are not ‘product liability actions,’” while citing no appellate authority supporting its conclusion.  The trial court acknowledged that the only on-point case, Lopez v. Huron, 490 S.W.3d 517 (Tex. App. 2016), was “potentially doubtful” because the statutory language did not limit its application to product liability actions. Cleveland, 2026 Tex. LEXIS 654, at *3.  That doubt led the trial court to grant the distributor’s request to appeal, framing the legal question: “whether [Section] 82.003(a) . . . applies to sellers in cases that are not product liability actions or whether it applies only to sellers in ‘products liability actions’ or cases where damages are allegedly caused by defective products.”  Id. (quotations omitted.)

That led to more obstruction.  The intermediate appellate court denied the petition, ruling that the distributor failed to show “‘a substantial ground for difference of opinion’ regarding the controlling legal question.”  Id. at *4.  That court also concluded that the absence of authority contrary to Lopez weighed against allowing the appeal.  Id.  Fortunately, the Texas Supreme Court disagreed—finding that while the existence of conflicting authority “strongly suggests a substantial ground for difference of opinion,” . . . “an actual conflict” is unnecessary “when the statute is subject to competing reasonable interpretations.”  Id.  The Texas high court cited the “express acknowledgment” in Lopez that its conclusion was at odds with Section 82.003(a)’s text as enough to establish “that reasonable jurists could disagree with Lopez regarding Section 82.003(a)’s scope.”  Id.  Conversely, the trial court acknowledged Section 82.003(a) has more than one plausible interpretation and that the Texas Supreme Court had yet to render a definitive decision on the issue.  Accordingly, there was “a substantial ground” for differing opinions under Tex. Civ. Prac. & Rem. Code § 51.014(d)(1) (providing the usual “controlling question” and “substantial grounds” test for interlocutory appeals by permission).  The Texas Supreme Court specifically stated that the “substantial ground for difference of opinion” standard is broad, rather than restrictive, designed to permit appeals of “genuinely disputed legal questions in varied contexts.”  Cleveland, 2026 Tex. LEXIS 654, at *5 n.1.

Further, while not deciding whether principles of statutory construction—discussed in the appellate court opinion—merited following Lopez, the Texas Supreme Court highlighted that the “potential clash with Section 82.003(a)’s plain text substantiates that an interlocutory appeal is appropriate.”  Id. at *5.  The court rejected the court of appeal’s reliance on “passing comments” in another case that stated only “that non-manufacturing sellers are not liable for product defects,” finding that action “indisputably involved alleged product defects.”  Id., citing Amazon.com, Inc. v. McMillan, 625 S.W.3d 101, 109 (Tex. 2021).

Against that backdrop, the Texas Supreme Court ruled that the appellate court erred in concluding that the distributor failed to satisfy the criteria for Section 51.014(d)(1) and never addressed the statute’s second requirement—whether “an immediate appeal . . . may materially advance the ultimate termination of the litigation.” Id., citing Section 51.014(d)(2).  In contrast, the trial court ruled an immediate appeal would “resolve a dispositive legal question prior to trial . . . because a ruling in [the distributor’s] favor” on Section 82.003(a) would “eliminate all potential claims.”  Id. at *5-6.  The court favorably cited prior appeals that obviated discovery burdens, “eliminate[d] the need for further litigation,” or would be dispositive of at least some of the claims against the defendants.  Id. at *6.

Plaintiffs argued an immediate appeal would “neither streamline the litigation nor dispose of all claims,” and that resolution of the applicability of the enumerated exceptions in Section 82.003(a) would not result in the distributor’s dismissal.  Id.  That was a straw man, as plaintiffs never alleged they met Section 82.003(a)’s exceptions, and therefore, if the statute applied, it would dispose of all the claims against the distributor—sufficient to satisfy Section 51.014(d)(2).  Id. at *6-7.  The Supreme Court emphasized that this was “precisely the kind of case in which an immediate appeal would allow for the efficient correction of error instead of risking the waste of judicial and party resources.”  Id. at *7 (emphasis added).

Thus, the “court of appeals erred in concluding that there was no substantial ground for difference of opinion” and should have granted the request for an appeal because “(1) the statutory construction question has not been decided by this Court and has more than one plausible answer and (2) resolution of the question may materially advance the litigation’s termination.”  Id.  Thankfully, the court granted the petition for review and ordered the appellate court to accept the appeal.  Id.  The Texas Supreme Court’s decision is one step in the right direction and gives the distributor and other sellers hope for the future.  This case still bears watching for a Texas two-step: a successful appeal and dismissal of the distributor under Section 82.003(a).

Photo of Eric Alexander

This post comes from the non-RS and non-Dechert side of the Blog.

The great post-modern existentialist philosopher John Madden once said, “If you have two quarterbacks, you actually have no quarterback.”  This was not the result of a fanciful math equation where you (impermissibly) divide by zero.  In American football, except on rare trick plays, only one quarterback will be on the field at the same time (even though up to six players on offense are eligible to throw the ball forward in a given play).  Splitting the practice and game snaps nearly evenly between two different quarterbacks tends to be a bad idea.  The saying does not really translate to the other football, except perhaps if you swap in “goalkeeper” for “quarterback.”  What about product liability claims?  Can two separate products cause the plaintiff’s claimed injury?  In most jurisdictions, depending on timing, yes.  What about 179 separate products to which the plaintiff was allegedly exposed on a regular basis for more than a decade leading up to the diagnosis of his claimed injuries?  No way.  We doubt that any complaint with that basic fact pattern could even make sufficient factual assertions to get past a motion to dismiss in federal court.

The plaintiff in Martinez v. Kraft Heinz Co., No. 2:25-cv-00377, 2026 WL 1878602 (E.D. Pa. June 30, 2026), sure could not do it in two tries and was not given a third chance.  The Martinez plaintiff claimed to have developed type 2 diabetes and steatohepatitis (fatty liver) by the time he was sixteen.  He blamed this on his collective use of 179 different food and beverage products that he had been voluntarily consuming on a regular basis since he was 3 years old.  His lawyers lumped these together as “Ultra Processed Foods” and threw together a very long and obviously templated complaint to detail the purported risks of these products, their ingredients, and aspects of their manufacturing.  Presumably, the core of these allegations could be used to try to support a general link between a bunch of different products and a range of diseases/conditions.  Perhaps, the individual products and their manufacturers were selected by the lawyers to be addressed in any complaint rather than coming from the actual list of what foods this plaintiff had been consuming regularly over that thirteen year period.  In any event, plaintiff’s first complaint failed to meet TwIqbal standards for causation, which was required for each of his asserted claims.  The “shotgun approach” did not “identify any specific products consumed by Martinez, when or how they were consumed, or how that consumption relates to Martinez’s diagnoses,” leaving it uncertain “who is responsible for what.”  Id. at *3.  Defendants had wisely removed this case from the Philadelphia Court of Common Pleas, where the pleading standards would surely have been more lenient. 

The amended complaint, presumably intended to correct the failures the court had previously identified, is what we are discussing here.  Perhaps because he knew he could not offer the required defendant- and product-specific allegations he needed, plaintiff also tried to get the court to bite on inapplicable theories of liability.  As it was, plaintiff’s second complaint attempted more misdirection and fearmongering rather than offering factual assertions that might have established legal causation.  “[A]llegations of increased risk, biological plausibility, and association do not show that any particular product—and particular Defendant’s product—actually caused Martinez’s diagnoses.”  Id. at *6.  None of the non-Pennsylvania law that plaintiff cited supported that his collective causation assertions could suffice for specific causation.  For us, there was a good source of the applicable law not discussed in Martinez that further supports the ruling.  Pennsylvania has Suggested Standard Jury Instructions, including one on “factual cause” that would have applied to plaintiff’s claims had they proceeded to trial.  The unaltered text of the current SSJI (Civ) § 13.20 is as follows:

In order for [name of plaintiff] to recover in this case, [name of defendant]’ s [negligent] [grossly negligent] [reckless] conduct must have been a factual cause in bringing about harm. Conduct is a factual cause of harm when the harm would not have occurred absent the conduct. To be a factual cause, the conduct must have been an actual, real factor in causing the harm, even if the result is unusual or unexpected. A factual cause cannot be an imaginary or fanciful factor having no connection or only an insignificant connection with the harm.

To be a factual cause, [name of defendant]’s conduct need not be the only factual cause. The fact that some other causes concur with [name of defendant]’ s negligence in producing an injury does not relieve [name of defendant] from liability as long as [his] [her] [their] own negligence is a factual cause of the injury.

The Subcommittee’s notes also cite a number of Pennsylvania cases explaining the specific causation standards, including in cases with multiple defendants, although none of them were cited in Martinez.  Taking even what seems to be plaintiff’s allegedly most-often consumed product, a particular brand of cheese slice, its contribution to plaintiff’s alleged injuries would undoubtedly be an “imaginary or fanciful factor having no connection or only an insignificant connection with” his alleged injuries when lumped together with 178 other allegedly harmful food items that plaintiff also regularly consumed.  Even if the complaint had been pared down to omit mention of most of the other allegedly harmful food items that plaintiff regularly consumed, it is hard to imagine a plausible allegation that the consumption of these cheese slices was “an actual, real factor” in him developing diabetes in light of his overall diet, to say nothing of his genetics, activity level, and other risk factors.  Without much more, it is even more implausible that the same 179 products were factual causes of both of plaintiff’s diagnoses.

Of course, plaintiff and his lawyers made the decision to target 179 different products sold by eleven different companies, which made it much harder to offer factual allegations sufficient to establish plausible specific causation under TwIqbal.  Were we deciding the adequacy of plaintiff’s complaints, we might have said plaintiff bit off more than he could chew or had eyes bigger than his stomach, but the Martinez court was overtly sympathetic to plaintiff.  It noted that the causation pleading requirement “creates a unique challenge for plaintiffs, like Martinez, who consume a large number of products over a lengthy period of time.”  Id. at *4.  Frankly, we draw the opposite conclusion from the court’s observation that “Martinez casts a wide net in seeking to hold numerous food producers liable for illnesses resulting from his consumption of nearly two hundred different products over the court of multiple years.”  Id.  It is not a failing of the law that plaintiff did not have a plausible causation story to assert.  It is not unfair that a defendant gets to insist that a liability be based on proof that its conduct caused plaintiff’s injury.  Plaintiff’s burden does not diminish because he sues ten other defendants and claims that 150 or so of their products also caused his injuries.  The court’s sympathy, though, led it to consider and reject plaintiff’s attempts to get special rules for cases like his.

Plaintiff dragged out Summers v. Tice and the Pennsylvania equivalent, Snoparsky v. Baer, 266 A.2d 707 (Pa. 1970), to suggest that he should get a lessened causation burden under an alternative joint liability theory.  Id. at *6-7.  Summers is the famous hunting accident case and Snoparsky involved a child’s injury from getting hit by a rock thrown by one of a group of rock-throwing children.  “[T]his doctrine exists to redress harms caused by one defendant from within a comprehensive, but otherwise limited, pool of potential harm-doers, only when determining fault is otherwise impossible.”  Id. at *7.  Plaintiff’s attempt to impose simultaneous liability on eleven manufacturers for making 179 products that were not alleged to be the only contributors to his alleged injuries was not remotely like the limited cases that had accepted this unusual theory.  The old DES case in the Philadelphia Court of Common Pleas that permitted alternative joint liability involved identical products made by multiple manufacturers that controlled substantially all the market but the plaintiff could not determine whose DES her mother took long ago.  Id. at *7-8 (discussing Erlich v. Abbott Labs., 5 Phila. 249 (Phila. Ct. Com. Pls. 1981)).  By contrast, the Martinez plaintiff’s suit sought to impose liability against eleven defendants that made many different products he claimed to have consumed.  The Eastern District of Pennsylvania had previously rejected the theory in another case seeking to impose liability for a physical injury on eleven defendants that made different products to which plaintiff claimed exposure over time.  Id. at *7 (discussing Klein v. Council of Chem. Assocs., 587 F. Supp. 213 (E.D. Pa. 1984)).  “[G]iven Pennsylvania’s hesitance to expand the alternative liability doctrine beyond those involving identical products,” the court could not take the “significant logical leap” to apply it to this case.  Id. at *8.  Had Martinez acknowledged the need for Erie restraint, the required leap would have been even harder.

Martinez also entertained the market share liability theory that had originated in the notorious California Sindell DES case.  It noted that the Southern District of New York had predicted, despite an acknowledgement of Erie restraint, that the Pennsylvania Supreme Court would likely adopt market share liability in a groundwater contamination case involving fungible products made by multiple manufacturers.  Id. at *8 (discussing In re Methyl Tertiary Butyl Ether (MTBE) Prods. Liab. Litig., 379 F. Supp. 2d 348 (S.D.N.Y. 2005)). The allegations in Martinez, however, were not close to that fact pattern, including because its defendants sold different products with different alleged problems.  If Martinez had checked the Blog, it would have seen a number of cases rejecting market share liability under Pennsylvania law in situations that were much closer to basic facts in Martinez, but a deeper dive was not needed to reject market share liability.  Nor did the court suffer the failing of many courts to give plaintiff a third bite at the proverbial apple:

The FAC fails to establish but-for causation because it lacks sufficient facts showing each Defendant or product individually caused or contributed to his harm.  Removing one Defendant or one product illustrates the deficiencies—the outcome would not change.  Alternative liability and market share liability cannot save Martinez’s claims because Defendants’ products and the dangerous chemicals contained therein are not the same.  For these reasons, leave to amend must be denied.

We note that Martinez did not go further and address whether plaintiff’s liability allegations were sufficient.  We have our doubts.  Plaintiff had alleged that all of the products were designed and marketed to “promot[e] subconscious overconsumption.”  In other words, the plaintiff lawyers were following the social media playbook that demonized the edible version of infinite scrolling and minimized personal responsibility.  The reptilian appeal of the typical plaintiff tactics may or may not translate to sweeping attacks on food and beverages, whether lumped together under the label of ultra-processed, genetically-modified, shelf-stable, or something else.  After all, ascribing negative mental health impacts to the plaintiff’s use of a specific application, website, or chat bot is a far cry from ascribing the plaintiff’s development of diseases that occur in the general population collectively to his consumption of a number of different foods and beverages over the course of many years.  As oversimplified, if not unscientific, as many discussions of public health have become, it would be particularly simplistic to make the precise source of the roughly 12 million calories that the plaintiff in Martinez would have consumed from when he started consuming the defendants’ 179 different products until he was diagnosed with type 2 diabetes and steatohepatitis the sole focus.  Designing or marketing a food so that people continue to buy and consume it does not sound tortious.  It sounds pretty normal.  By contrast, how a company’s particular food products fit into larger public health issues like increasing rates diabetes diagnoses among teens is very complex.

Photo of Stephen McConnell

Lately, weirdly, sadly, some people have suggested that the Enlightenment was a mistake. They contend that an overemphasis on rationality robbed humanity of feeling, faith, etc. What drivel. Every day of the week, we’ll take Voltaire over any pretend-King, data over dogma, and science over stupidity. 

Thus, we are pleased with Miller v. McDonald, 2026 WL 1871521 (2d Cir. June 30, 2026), another appellate win for mandatory school vaccination requirements.  

The opinion begins with a recitation of New York’s history of regulating immunization in schools. In 1860, New York empowered school officials to deny admission of unvaccinated students. There were exemptions for students who could not be vaccinated for medical reasons or those whose parents held religious objections. Much more recently, in 2018-19, New York became the epicenter of a measles outbreak. Following that outbreak, the legislature repealed the religious belief exemption but not the medical exemption. Various Amish community schools and their officials brought this lawsuit under 42 USC section 1983, alleging that the immunization law infringed their free exercise rights under the First and Fourteenth Amendments. The plaintiffs also argued that the law impaired the right of parents to control the religious upbringing of their kids. 

The plaintiffs relied on Wisconsin v. Yoder, 406 U.S. 205 (1972), a case studied by pretty much everyone who attended law school over the last 50 years. In Yoder, the Supreme Court held that the First Amendment free exercise right of Amish parents outweighed the state’s interest in compelling school attendance beyond eighth grade. That precedent might not be precisely on point, but it is pretty helpful for the plaintiffs. But it was not helpful enough.  

The district court in Miller granted the state’s motion to dismiss and the Second Circuit affirmed. But then the United States Supreme Court granted certiorari, vacated the judgment, and sent the case back for reconsideration in light of Mahmoud v. Taylor, 606 U.S. 522 (2025). In Mahmoud, the Supreme Court overturned a school board’s refusal to allow parents to opt their young children out of classroom instruction using storybooks that conveyed messages contrary to the parents’ religious briefs.  

Thus, the Miller plaintiffs got a do-over. But after going through an analysis of the free exercise claims and the interplay of Mahmoud with Yoder, the Second Circuit decided it had been right all along and, again, affirmed dismissal of the case. Again, the Second Circuit held that New York did not act unconstitutionally when it repealed its religious exception to mandatory vaccination following a measles outbreak.  

The Second Circuit began its analysis with the observation that generally applicable vaccination requirements do not unconstitutionally burden the free exercise of religion. For the umpteenth time, we are treated to a citation to the Jacobson (1905) case in which the Supreme Court upheld a Massachusetts law requiring vaccination against smallpox. A neutral vaccination mandate need pass only rational basis review.  By contrast, a vaccination law animated by hostility to a particular religious sect would face fatal-in-fact strict scrutiny. As in Jacobson, the New York vaccination mandate was religiously neutral, and addressed a legitimate governmental interest in preventing communicable disease. It was an easy rational basis case. “Government is generally free to place incidental burdens on religious exercise so long as it does so pursuant to a neutral policy that is generally applicable.”  Repealing a religious exemption does not transmute an otherwise neutral law into one that targets religious belief.  The legislative history, read as a whole, does not show religious bias. (There might have been some isolated bits supporting the plaintiffs’ suspicion of bias, but they were isolated and unrepresentative, and serve as reminders of why Justice Scalia was deeply skeptical of legislative history.) Providing medical exemptions does not require providing religious ones.  The two are not comparable.  The medical exemption is the same as other vaccination exemptions that are constitutionally permissible.  

Further, mandatory vaccination does not unconstitutionally burden parental rights.  It is a general health requirement that does not seek to change any child’s religious belief. The burden of mandatory vacination “is not remotely of the same character as those imposed in Yoder and Mahmoud. The law is a public health measure, not an instrument of ideological indoctrination. It does not expose children to values or beliefs that might be hostile to their parents’ religious beliefs.”

Score one for public health. And while we’re at it, score one for leading figures of the Enlightenment, such as Montesquieu, Adam Smith, and, yes, John Adams and Thomas Jefferson. 

Post-script: On June 29, the Supreme Court denied certiorari in another vaccine-related appeal, Doe v. Hochul, from another Second Circuit/NY decision, that made similar religiously based attacks on mandatory vaccination, in that case, employment-related.  Doe had been hanging around all term, with more than the average amount of activity,  https://www.scotusblog.com/cases/does-1-2-v-hochul/.

The day after the denial, the Second Circuit handed down Miller.  Maybe a coincidence, maybe not.

Photo of Michelle Yeary

We have written before about the Taxotere eye injury MDL — and we wish we could say things were getting better. They are not.

Last December, we noted the fundamental absurdity at the heart of this litigation. Cancer patients — many of them breast cancer patients — were given Taxotere, a chemotherapy drug. The label warned that excessive tearing “may be attributable to lacrimal duct obstruction.” Plaintiffs’ lawyers, never ones to let adequate warnings stand in the way of a good MDL, decided that was not good enough. They wanted the label to say the tearing may be caused by “stenosis of the nasolacrimal drainage system.” And so we have, as we put it before, thousands of lawsuits, nearly a decade of litigation, and only the lawyers reaping anything other than minimal benefit.

Now the same MDL court has denied the defendant’s motion for summary judgment on warning adequacy. In re Taxotere (Docetaxel) Eye Injury Products Liability Litigation, 2026 WL 1839097 (E.D. La. June 25, 2026). The court managed to find genuine disputes of material fact lurking in what is, at bottom, a series of complaints that could be described as the medical terminology equivalent of arguing about whether a “hot dog” is a “sandwich.” The court did not even bother to apply the law of any particular state, applying instead a kind of generalized, multi-jurisdictional soup of failure-to-warn principles. The result is a roadmap for how to nitpick a warning to death.

Let us count the ways plaintiffs were permitted to pick apart an otherwise adequate warning.

Number 1. The label warned of “lacrimal duct obstruction.” Plaintiffs argued it should have said “nasolacrimal drainage system.” The defendant’s regulatory expert opined there was no material distinction between the two — that “nasolacrimal” and “lacrimal” do not “inherently change the characterization of the condition or impart additional or more useful information for the prescriber.” Id. at *5. On the other side, one of plaintiffs’ experts opined that “lacrimal duct obstruction is not terminology he uses in his practice.” Id. He didn’t say he didn’t understand the term, just that he personally does not use it. The court found a jury question. We find an eye roll.

Number 2. The defendant pointed to Stedman’s Medical Dictionary, which defines “obstruction” as a “blockage or clogging, e.g., by occlusion or stenosis.” Id. at *4. Stenosis, in other words, is one of the things that causes obstruction. Obstruction is the thing the label warned about. So the label warned about the thing caused by the thing plaintiffs say should have been mentioned. Plaintiffs countered with a different edition of the same dictionary that defines stenosis as a “narrowing” and cautions not to confuse it with “occlusion.” Id. The court found a jury question. We find it hard to keep a straight face.

Number 3. The label did not specifically say the condition could become permanent. Plaintiffs say it should have. To compound matters, the label noted that certain visual disturbances were “reversible upon discontinuation of infusion.” Defendant argued, correctly, that this referred to the immediately preceding sentence about transient visual disturbances during infusion — not to lacrimal duct obstruction, which appeared several sentences earlier. The court disagreed. Viewing everything in the light most favorable to plaintiffs, the court found a jury could conclude the label misleadingly implied the tearing risk was also reversible. Id. at *6.

Number 4. Plaintiffs’ expert opined the label should have warned physicians to promptly refer patients to an ophthalmologist upon signs of excessive tearing and mentioned the potential need for surgical intervention. This, as we have noted before, is the pharmaceutical equivalent of requiring a car manufacturer to tell drivers how to parallel park. Labels are not required to instruct physicians on how to practice medicine. The court acknowledged that manufacturers generally need not instruct physicians how to manage disclosed side effects, but found this wasn’t necessarily a “management instruction” and again found a jury question. Id. at *6.

And number 5. On top of all of that, plaintiffs’ expert opined the warning should have appeared in the “Warnings and Precautions” section rather than in the “Adverse Reactions” section. The court let that theory survive too. Id. at *7. This, again, is a theory we have seen before and continue to find unpersuasive — especially for a risk that is, let’s remember, associated with a chemotherapy drug being given to cancer patients.

Before getting to the merits of the warning claims, the court noted something worth flagging: it wasn’t going to apply the law of any particular state. Plaintiffs didn’t argue for an individualized choice-of-law analysis, and the court was apparently content to proceed under a generalized “common principles” approach. Id. at *4.

In an MDL involving thousands of plaintiffs from dozens of states, that is a curious thing. The whole point of Erie is that federal courts sitting in diversity apply state law — not a blended smoothie of principles that happen to be shared by most states. Different states have different standards for warning adequacy. Some apply the learned intermediary doctrine more rigorously; some have statutory presumptions; some are more forgiving of general warnings; some require specific causal language. A ruling that deliberately declines to engage with any of that is a ruling built on a foundation that can shift at any moment — which is bad for everyone, including plaintiffs, though they may not see it that way right now.

Even setting aside all of the above, we are compelled to return to the point we made in December, because it has not gotten any less true: these plaintiffs still have to prove warnings causation.

Under the learned intermediary doctrine — which the court acknowledges applies here — adequacy is measured by whether the prescribing physician would have reasonably understood the risk. Id. at *3. And even if the jury somehow finds the warning inadequate, each plaintiff must then show that a different warning would have changed her oncologist’s prescribing decision.

So. How many oncologists are going to take the stand and testify: “Yes, I would not have prescribed potentially life-saving chemotherapy to this very sick cancer patient had I only been formally instructed that the excessive tearing due to duct obstruction was because of stenosis of the nasolacrimal drainage system, and that I should refer to an ophthalmologist promptly”?

In a non-insane world, this should be something very difficult to prove. Oncologists treat cancer. They weigh the risks of chemotherapy — real risks, like neutropenia, neuropathy, and secondary malignancies — against the risk of dying from cancer. The suggestion that the difference between “lacrimal duct obstruction” and “stenosis of the nasolacrimal drainage system” would have led any oncologist to withhold chemotherapy from a cancer patient strains credulity past the breaking point.

But here we are. Thousands of cases. Nearly a decade. And counting.

If beauty is in the eye of the beholder, this MDL court seems to see beauty in every alleged gap in a warning label — no matter how fine the distinction, no matter how unlikely it would have changed anything, and no matter what state’s law is supposed to govern.